SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions March list of published pending patents 03/07

20070071670 - Diagnostic imaging agents with mmp inhibitory activity: The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the... Agent: Ge Healthcare, Inc.

20070071671 - Process for producing radioactive-fluorine-labeled compound: An on-column process by which various radioactive-fluorine-labeled compounds can be obtained in a high yield. The process comprises a step in which [18O] water containing [18F] fluoride ions is introduced into a column packed with an anion-exchange resin for labeled-compound synthesis to collect the [18F] fluoride ions, a step in... Agent: Sughrue Mion, PLLC

20070071673 - Trifunctional reagent for conjugation to a biomolecule: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with... Agent: Swanson & Bratschun L.L.C.

20070071672 - Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents: The invention relates to the use of metal tricarbonyl compounds of the general formula [M(CO),L,]′, wherein M is rhenium or technetium or an isotope thereof and L is a ligand, for the preparation of a medicament for the treatment of cancer that is both radiotherapeutic and chemotoxic when a radioactive... Agent: Jerad Seurer Mallinckrodt Inc.

20070071675 - Dual variable domain immunoglobulin and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.... Agent: Abbott Bioresearch

20070071676 - Methods and therapies for treating inflammatory conditions with exposed collagen: Compositions and methods for treating and imaging vulnerable plaque and other inflammatory conditions in a patient rely on the delivery of conversion electron-emitting sources and other radionuclides to regions of exposed collagen in the vasculature or other body lumens. The conversion electron-emitting sources or other radionuclides are coupled to a... Agent: Townsend And Townsend And Crew, LLP

20070071674 - Polynucleotides encoding novel isoforms of igsf9: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070071678 - Electrical initiation system: An apparatus and method of using electrically initiated primer systems that rely on vaporizing a thin metallic film which is either coated on a non-conductive insulator component or is a malleable thin film or strip secured to the inner surface of a primer cup assembly to ignite an environmentally safe... Agent: Navairwd Counsel Group

20070071677 - Non-toxic membrane-translocating peptides: Compositions for transport across a biological membrane include a membrane-translocating LMWP peptide and a cargo molecule. Methods for transporting a cargo molecule across a biological membrane are also described.... Agent: Mayer, Brown, Rowe & Maw LLP

20070071680 - Methods and compositions for preparing consumables with optical shifting properties: Ingestible compositions comprising a chromic change agent together with methods of making and using them are provided. The chromic change agent alternatively may be associated with the ingestible, such as a packaging material for the ingestible. In response to a triggering event, physical or chemical, the chromic change agent changes... Agent: Bozicevic, Field & Francis LLP

20070071679 - Methylamine risks and treatment of hyperactivity, depression, and alcoholism with epinephrine-n-quinolines: Results of animal experiments proving a relationship between ontogenetically early sleep-wake behaviour and neurobehavioural disorders during later life indicate examination of ontogenetically early sleep-wake behaviour in human beings. With drugs with N-adrenaline moiety and with drugs with PNMT-inhibiting activity, in addition with effects on adrenergic beta and alpha-1 receptors, and... Agent: Ilkka Tapio Hilakivi

20070071681 - Apparatus and method for computer modeling type 1 diabetes: The invention encompasses novel methods for developing a computer model of type 1 diabetes in a mammal. In particular, the models can include representations of biological processes associated with a pancreatic lymph node and one or more pancreatic islets. Alternatively, the models can include representations of biological processes associated with... Agent: Entelos, Inc. C/o Foley & Lardner LLP

20070071682 - Methods for testing vaccine candidates against bacterial infection in rodents: Methods and a rodent model to test the effectiveness of vaccine candidates against bacteria, e.g., Staphylococcus aureus by systemically immunizing a rodent, particularly a cotton rat, with a vaccine candidate, intranasally challenging the cotton rat with the selected bacteria, and detecting a response with respect to an immune response, nasal... Agent: Lahive & Cockfield, LLP

20070071683 - Ultrasonic concentration of carrier particles: Methods, compositions, and apparatus for localized delivery of compounds are provided. In certain embodiments, acoustic streaming force is used to direct carrier particles to a target site, mediate particle internalization, and release associate compounds. Ultrasound radiation is preferred as the source for the acoustic streaming force. Also encompassed are embodiments... Agent: Fenwick & West LLP

20070071685 - Gas-filled microvesicle assembly for contrast imaging: Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC may optionally comprise a targeting ligand, a bioactive agent, a diagnostic agent or any... Agent: Bracco Research Usa Inc.

20070071684 - Process for the preparation of surface coatings and films: A method of coating the surface of a substrate which comprises the steps of: i) contacting the surface with a polymerisable mixture comprising one or more polymerisable components and containing suspended droplets of a biliquid foam or of a high internal oil phase emulsion, the said droplets being stabilised by... Agent: Dykema Gossett PLLC

20070071687 - Intranasal benzodiazepine compositions: A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt thereof; and a nasal carrier. In some embodiments, the pharmaceutical composition when administered intranasally produces a rapid physiological response. Pharmaceutical compositions may also include at least one... Agent: Mayer, Brown, Rowe & Maw LLP

20070071686 - Liquid preparation containing tobramycin: The application describes a sterile aqueous inhalation solution containing the active agent tobramycin. The preparation has a high content of active agent (about 80 to 120 mg/ml of tobramycin) and contains an acidic adjuvant, but contains only a low concentration of sodium chloride (at most about 2 mg/ml). It can... Agent: Edwards & Angell, LLP

20070071688 - Pharmaceutical compositions for transdermal administration of anti-inflammatory agents: A pharmaceutical composition for transdermal administration comprising a polymeric release matrix capable of forming a supple film after drying, selected among cellulose polymers or copolymers; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least one carboxylic or metal carboxylate group; a transcutaneous absorption promoter; water;... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070071689 - Advantageous combination for inhalation of nacystelyn and bronchodilators: pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.... Agent: Lowe Hauptman Berner, LLP

20070071692 - Aerosol powder formulation: This invention relates to dry power aerosol formulations for use with a dry powder inhaler, the formulation comprising the PDE 4 inhibitor N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide:... Agent: Merck And Co., Inc

20070071691 - Composition: Dry powder pharmaceutical compositions having improved storage stability, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070071690 - Dry powder formulations: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070071694 - Composition for oral cavity: The invention relates a composition for oral cavity for preventing adhesion of Porphyromonas gingivalis as periodontopathic bacterium to oral tissue. The invention also relates to a composition for oral cavity containing a peptide in which arginine and histidine bind alternately. Preferably, the invention includes a composition for oral cavity including... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070071693 - Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases: The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. According to the present invention, there are provided therapeutic agents for periodontal diseases and... Agent: Drinker Biddle & Reath (dc)

20070071696 - Dual phase whitening dentifrice: A dual phase whitening oral care composition comprising a first phase comprising a bound peroxide in a substantially anhydrous carrier and a second phase comprising an abrasive and a tartar control system in an orally acceptably carrier. Methods of whitening a tooth surface are also provided.... Agent: Colgate-palmolive Company

20070071695 - Single phase whitening dentifrice: The invention provides a single phase whitening dentifrice that includes (i) a whitening agent selected from the group consisting of hydrogen peroxide, a bound peroxide and a solid peroxide (ii) an abrasive and (iii) a substantially anhydrous orally acceptable carrier, for example, polyethylene glycol. The bound peroxide may be hydrogen... Agent: Colgate-palmolive Company

20070071699 - Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening: are useful active agents for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or preventing and/or limiting the depigmentation and/or bleaching thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for preventing and/or limiting the canities of human keratin... Agent: Buchanan, Ingersoll & Rooney PC

20070071697 - Therapeutic soap product with uv protection: The present invention concerns a cleansing composition that imparts sun protection for the skin through normal daily use during bathing, washing, or cleaning of the body or face. The cleansing composition of the present invention comprises a unique combination of ingredients that provides therapeutic and restorative properties for the skin.... Agent: John J. Yim, Esq.

20070071698 - Therapeutic soap product with uv protection: The present invention concerns a cleansing composition that imparts sun protection for the skin through normal daily use during bathing, washing, or cleaning of the body or face. The cleansing composition of the present invention comprises a unique combination of ingredients that provides therapeutic and restorative properties for the skin.... Agent: John J. Yim, Esq.

20070071700 - Cosmetic compositions containing silicone/organic copolymers: A cosmetic composition comprising at least one lipophilic liquid alkoxylated film forming polymer comprised of siloxane portions and urethane portions.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070071701 - Antiperspirant actives and compositions: Polyol-sprayed particulate antiperspirant actives, methods of manufacture thereof, and compositions comprising polyolsprayed particulate antiperspirant activities and carrier materials are described.... Agent: Unilever Intellectual Property Group

20070071703 - High efficiency master gels for thickening oil based compositions: The composition, preparation and use of a thickening system or master gel for oil based compositions, especially cosmetic compositions is described. These highly efficient master gels include: i) greater than about 10% to about 40% of an organoclay, ii) from about 70% to less than about 90% of a carrier... Agent: Michael P. Aronson Mp&g Aronson Inc.

20070071704 - Silicone-in-water emulsion compositions containing retinoids: The present invention relates to a composition containing a retinoid wherein the composition is a silicone-in-water emulsion, and the use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070071706 - Lipodissolving dermatological topical preparation: A dermatological topical preparation such as a cream, a lotion, an emulsion, a paste, an ointment and the likes where a lipo-dissolving emulsifier such as a biliary compound is transdermally delivered through the superficial layers of the skin into the subcutaneous adipose tissue with the use of skin permeability enhancers.... Agent: Filiberto Zadini

20070071705 - Topical anti-microbial compositions: Topical anti-microbial compositions, and more particularly anti-bacterial and anti-fungal compositions, comprising a therapeutically effective amount of an anti-microbial agent, a starch, a hydroalcoholic solvent, and a volatile silicone compound having a viscosity of about 0.1 to about 50 centistokes. These compositions are capable of temporarily or permanently reducing, inhibiting, treating,... Agent: Nath & Associates

20070071707 - Composition and method of transmitting ultrasonic and electrical impulses using a physiologically compatible conductive agent: The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to... Agent: Richard R. Muccino

20070071708 - Anhydrous hair compositions comprising a phosphate ester: A composition and process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: (a) at least one alkoxylated alkyl phosphate ester; (b) at least one ester oil component; and (c) optionally, at least one non-ester oil component.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070071709 - Hair cosmetic composition: (B) a C8-30 aliphatic alcohol, and (C) toluenesulfonic acid or salt thereof. The hair cosmetic composition is excellent in the effect of restoring the flyaway or waved hair, which has appeared as a result of accumulation of damage due to hair coloring or the like, to its former state before... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070071702 - Use of a polyguanidine compound for treating or shaping the hair, especially for straightening or permanent-waving it: The present invention relates to the use of a cosmetic composition containing compounds derived from polyguanidines or physiologically acceptable salts thereof for the protection of keratin fibres during permanent-shaping treatments or hair-straightening operations. The invention also relates to a cosmetic treatment process for permanently shaping or straightening keratin fibres, such... Agent: Steptoe & Johnson LLP

20070071710 - Extract of vanilla planifolia: The invention relates to an extract of vanilla originating from at least one species of vanilla plant (family Orchidaceae), to the method for obtaining it, to a cosmetic or dermatological composition containing it, and to its use as a polyfunctional active agent in a cosmetic or dermatological composition, for the... Agent: Hunton & Williams LLP Intellectual Property Department

20070071711 - Formulations for topical delivery of bioactive substances and methods for their use: The invention relates to topical delivery of bioactive agents. More particularly, the invention relates to anhydrous formulations for percutaneous absorption. The invention provides formulations that allow efficient topical delivery of high concentrations of bioactive substances for percutaneous absorption. The formulations according to the invention are generally non-irritating to the skin.... Agent: Keown & Associates

20070071713 - Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents: The present invention describes compositions and methods for trapping/capturing and/or destroying dangerous substances such as chemical and biological warfare agents. The present invention relates to dendritic polymers, specifically, to quaternary ammonium functionalized dendritic polymers and N-Halamine functionalized dendritic polymers. Such dendrimers are useful for the capture and neutralization of biological... Agent: Pepper Hamilton LLP 50th Floor

20070071715 - Methods and compositions for phosphate binding: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a... Agent: Quarles & Brady LLP

20070071712 - Polymer network compositions and associated methods: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.... Agent: Baker Botts L.L.P. Patent Department

20070071714 - Stem cell factor: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070071716 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Bell, Boyd, & Lloyd LLP

20070071717 - Treatment of b cells with il-21 and b cell activators induces granzyme b production: The present invention involves the combined use of IL-21 and TLR agonists such as CpG oligonucleotides in the treatment of B cell cancers and B cell-related immune pathologies such as autoimmune diseases. In addition, it is demonstrated that human B cells produce and secrete varying amounts of Granzyme B in... Agent: Fulbright & Jaworski L.L.P.

20070071718 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071719 - Compositions and methods for regulation of tumor necrosis factor-alpha: The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.... Agent: Medlen & Carroll, LLP

20070071720 - Method of treating hepatitis b viral infection: The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis B infections. The present invention also provides a method for treating chronic hepatitis B infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070071721 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070071723 - In vivo enhancement of immune system recognition of neoplasms following treatment with an oncolytic virus or gene therapy vector: This invention provides novel methods of treating or alleviating neoplasms and enhancing the efficacy of oncolytic viruses by administering an oncolytic virus to a mammal suffering from a neoplasm and subsequently administering an immunostimulant. The invention also provides methods of increasing immunorecognition of neoplastic cells.... Agent: Fish & Richardson P.C.

20070071724 - Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity: The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also... Agent: Wilmerhale/columbia University

20070071725 - Nitric oxide synthase gene transfer: This invention relates to to gene transfer, specifically, provided herein are methods, vectors and compositions for the transfer of nNOS gene affecting overexpression of nNOS in sympathetic and parasympathetic nervous system and its subsequent use in the treatment of related pathologies.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070071722 - Nucleotide vaccine composition: The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting... Agent: Dinsmore & Shohl, LLP

20070071726 - Recombinant viral-based malaria vaccines: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are... Agent: Trask Britt

20070071734 - Arpe-19 as platform cell line for encapsulated cell-based delivery: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice;... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070071735 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070071736 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070071737 - Live bacterium preparation containing lactic acid bacterium as active ingredient and food containing lactic acid bacterium: Disclosed is a live bacterium preparation or food containing a lactic acid bacterium comprising a lactic acid bacterium, Lactobacillus salivarius, as an active ingredient. There is provided a live bacterium preparation and food containing a lactic acid bacterium that can prevent onset, recurrence and exacerbation of periodontal disease and/or dental... Agent: Bacon & Thomas, PLLC

20070071738 - Propionibacterium p-63 for use in direct fed microbials for animal feeds: A ruminant direct fed microbial composition of matter comprising an acidosis inhibiting effective amount of Propionibacterium P-63 is provided. Also disclosed is a process for reducing acidosis in ruminants or scours in swine by administration of the bacterium to the ruminant or swine. The microbial composition may be administered by... Agent: Fellers Snider Blankenship Bailey & Tippens

20070071739 - Treatment of bipolar disorder utilizing anti-fungal compositions: A method for treatment or prophylaxis of a bipolar disorder disease state, by administration of an anti-fungal composition that includes at least one of the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium.... Agent: Intellectual Property / Technology Law

20070071728 - Biomimetic nanocomposite: A biomimetic nanocomposite including hydroxyapatite nanocrystals, gelatin, and polymer, wherein the biomimetic nanocomposite is crosslinked is described. Also described is a process for making the nanocomposite. Additionally, a method for using the nanocomposite, and articles formed from the nanocomposite are also described.... Agent: Fish & Richardson P.C.

20070071729 - Dermal fillers for biomedical applications in mammals and methods of using the same: A method of tissue augmentation in mammals comprising implanting or injecting into the tissue of a mammal elastic material derived from solar elastosis or other sun-damaged sites in humans is disclosed. The method further comprises injecting into the tissue of a mammal, alone, or in combination with the solar elastosis,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071727 - Melanocytes in therapy of neurodegenerative diseases: In vitro cultivation method for producing human melanocytes which are capable of melanin and/or L-dopa synthesis, and to various uses of said melanocyte(s). In one preferred aspect, said melanocyte(s) are used in an autologous implantation method in a patient suffering from a neurodegenerative disease, e.g. Parkinson's disease. In another aspect,... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070071731 - Promotion of neurogenesis of endogenous and transplanted human neural stem cells: Disclosed herein are methods and materials for promoting neurogenesis of endogenous and transplanted stem cells. Specifically exemplified herein are methods that comprise transplanting neural stem cells in conjunction with a regimen of (+)phenserine treatment.... Agent: Beusse Wolter Sanks Mora & Maire

20070071732 - Secretory cell-containing macrobeads comprising seakem gold agarose, and uses thereof: The invention describes the manufacture and use of secretory cell containing bead structures that are coated with agarose. The beads, which are preferably 4 mm-12 mm in diameter, and which preferably contain islets, are made of a particular agarose, i.e., Seakem Gold agarose.... Agent: Fulbright & Jaworski, LLP

20070071730 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070071733 - Synthetic substrate for tissue formation: The invention relates to a substrate on which to grow synthetic cartilage, a method for preparing the substrate, a synthetic cartilage patch comprising the substrate, and methods of using the synthetic cartilage patch.... Agent: Howson And Howson

20070071740 - Purified amniotic membrane compositions and methods of use: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20070071741 - Ocl-2a3 compositions and uses thereof: This invention relates to osteoclast-specific genes and proteins. Specifically, the invention relates to OCL-2A3 or Atp6v0d2, the gene encoding it and uses thereof in methods and treatment of bone disorders.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070071742 - Humanized antibodies: Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID... Agent: Mr. Robert M. Jaffe

20070071743 - Novel human cell surface protein with immunoglobulin folds, bgs-19: The present invention provides novel polynucleotides encoding BGS-19 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying the novel BGS-19 polypeptides to the diagnosis, treatment, and/or prevention... Agent: Louis J. Wille Bristol-myers Squibb Company

20070071744 - Agents which bind to epitopes of glycoprotein vi: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.... Agent: Klarquist Sparkman, LLP

20070071746 - C/clp antagonists and methods of use thereof: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for... Agent: Johnathan Klein-evans

20070071745 - Modified antigen binding molecules with altered cell signaling activity: The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071748 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071749 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071747 - Use of tnfalpha inhibitor for treatment of erosive polyarthritis: The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.... Agent: Lahive & Cockfield, LLP

20070071751 - Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and... Agent: Sheridan Ross PC

20070071750 - Human antibody variants that specifically recognize the toxin cn2 from centruroides noxius scorpion venom: The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071752 - Sphingosine kinase enzyme: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070071759 - Antibody-immune cell ligand fusion protein for cancer therapy: Compositions for treatment of cancer comprising chimeric fusion molecules that bind to an antigen on a pathogenic cell and to an immune cell. The molecules redirect the immune cells to a pathogenic cell. The purified fusion proteins demonstrated ability to bind antigen on the surface of tumor cells and cell... Agent: Akerman Senterfitt

20070071758 - Ceacam1 based cancer therapy and diagnosis: The invention relates to methods and compositions for the treatment and diagnosis of cancers. At least one aspect of the present invention relates to methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (TIL) therapy in the treatment of cancer by negatively modulating the activity of the CEACAM1 protein.... Agent: Mcandrews Held & Malloy, Ltd

20070071762 - Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac): The present invention provides methods of assessing and selecting treatment modalities for cancer.... Agent: Connolly Bove Lodge & Hutz LLP

20070071756 - Delivery of an agent to ameliorate inflammation: A method delivering an anti-vascular endothelial growth factor (VEGF) agent to ameliorate inflammation at a site in the body that may be the eye, a joint, the brain, etc. or to reduce corneal neovascularization. In one embodiment, one or more other agents, such as non-steroidal anti-inflammatory agents, steroids, etc., may... Agent: Wood, Herron & Evans, LLP

20070071753 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 85 (gpr85): The invention provides a human GPR85 which is associated with the cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, hematological... Agent: Banner & Witcoff

20070071761 - Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody: The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer including tumors and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic... Agent: Hodgson Russ LLP

20070071754 - Method to ameliorate inflammation: Administering to a patient a concentration of at least one anti-inflammatory agent and bevacizumab at a concentration sufficient to reduce fluid leakage from new vessels associated with angiogenesis.... Agent: Wood, Herron & Evans, LLP

20070071760 - Methods for treating b-cell malignancies using a taci-ig fusion molecule: The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.... Agent: Howrey LLP

20070071757 - Novel compositions and methods in cancer: This invention is in the field of cancer-associated (CA) genes. Specifically it relates to methods for detecting and diagnosing cancer or the likelihood of developing cancer based on the presence or absence of expression of PRDM11 or TBX21 or proteins encoded by those genes. The invention also provides methods and... Agent: Sagres Discovery Inc. Intellectual Property - R440

20070071755 - Novel nucleolar gtpases and method for controlling proliferation of cells: There is provided an isolated polypeptide comprising an amino acid sequence at least 85% homologous to SEQ ID NO: 2 or SEQ ID N: 4, or a conservative variant thereof, wherein the polypeptide regulates proliferation of a cell. There is also provided an isolated polynucleotide encoding the polypeptide of the... Agent: Morgan Lewis & Bockius LLP

20070071763 - Clostridium difficile focussed antibodies: The present invention is concerned with antibodies specific for and which confer immunity against infection by C. difficile or against a vaccine, methods of identifying same, methods of manufacture of medicaments, and methods of treatment of patients using same. Also provided is a method for determining the efficacy of a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070071764 - Toxin peptide therapeutic agents: and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or... Agent: Amgen Inc.

20070071765 - Compositions for immunotherapy and uses thereof: The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071766 - Compositions comprising fungal immunomodulatory protein and use thereof: This present invention relates to fungal immunomodulatory proteins, compositions and method for use in immunotherapy, treating or preventing cancer due to metastasis or suppression of telomerase activity by down-regulation of the telomerase catalytic subunit (hTERT), activating natural killer cells, macrophage or increasing serum antibody. The present invention also relates to... Agent: Harness, Dickey & Pierce, P.L.C

20070071767 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070071768 - Use of rip in treating staphylococcus aureus infections: The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition... Agent: Merchant & Gould PC

20070071769 - Recombinant mva virus, and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071770 - Recombinant mva virus, and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071771 - Method for limiting the growth of cancer cells using an attenuated measles virus: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells... Agent: Fish & Richardson P.C.

20070071772 - Treatment of metastatic colon cancer with b-subunit of shiga toxin: The present invention relates to compositions and methods for treating invasive or metastatic cancer, particularly metastatic colon cancer using the B-submit of shiga toxin. The invention further provides methods of identifying compounds usefully for the treatment of invasive or metastatic cancer, particularly metastatic colon cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20070071773 - Compositions and methods for the treatment and prophylaxis of infections caused by gram positive bacteria: The invention relates to methods of treatment, compositions and uses of an isolated and purified peptide for the inhibition of an invasive and/or non-invasive infection of Gram-positive pathogenic bacteria. A specific peptide comprises an amino acid sequence substantially homologous to the amino acid sequence encoded by the SilCR ORF of... Agent: Cooper & Dunham, LLP

20070071774 - Protein d - an igd-binding protein of haemophilus influenzae: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071775 - Attenuated strains of vibrio cholerae with improved biological safety features in freeze dried form for oral vaccination: The present invention discloses new live attenuated strains for oral immunization against cholera that are provided in freeze dried formulations for long term storage and administration to humans. These strains combine the two most important properties of live attenuated cholera vaccine candidates. One such property is being well tolerated by... Agent: Defillo & Associates, Inc.

20070071776 - Recombinant vaccine against fish infectious diseases: A recombinant vaccine that is useful for immunizing fish against ciliated ectoparasitic protozoans that cause white spot disease also known as ‘ich’. The disease is caused by Ichthyophthirius multifiliis which is a ciliated ectorparasitic protozoan that is an obligate parasite and therefore cannot grow in vitro. The instant vaccine replaces... Agent: Lowe Hauptman Berner, LLP

20070071779 - Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof: A composition for delivering lipophilic agents to intestinal mucosa and method of making and use thereof are disclosed. The composition comprises an aqueous solution of one or more short chained C2 to C6 fatty acids, and corresponding salts thereof, and one or more lipophilic agents dissolved in the aqueous solution.... Agent: Advantia Law Group

20070071777 - Oil emulsion for postnatal hormone substitution: The invention relates to a process for the preparation of hormone-containing oil emulsions (lipid emulsions), an isotonic oil emulsion obtainable by such process, and the use of the emulsion according to the invention for the preparation of a medicament for intravenous administration, especially for postnatal hormone substitution in premature babies... Agent: Christie, Parker & Hale, LLP

20070071778 - Stable microemulsion concentrate for delivery of a bioactive biocide/disinfectant/fungicide/fragrance in an aqueous medium providing sustained release: What is described herein is a stable microemulsion concentrate and composition for delivery of an active biocide/disinfectant in an aqueous medium providing sustained release of the active. The composition is effective against both bacteria and fungi.... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070071781 - Compositions for rupturable capsules and methods of making the same: A rupturable capsule that includes a capsule containing a composition is disclosed. Also disclosed are compositions that include silica, oil, a bioorganic filler, colorant, fragrance, and a combination thereof. A method of imparting a colorant, a fragrance, and a combination thereof to an object, that includes rupturing a rupturable capsule... Agent: Michael Best & Friedrich, LLP

20070071780 - Personal care composition comprising a perfume booster accord: A personal care composition comprising a perfume booster accord. The human nose can detect the odor of the perfume booster accord at low concentrations. The perfume booster accord also provides a bigger bloom and longevity of scent. The present invention is further directed to a method of using the personal... Agent: The Procter & Gamble Company Intellectual Property Division

20070071782 - 2-cyanobenzenesulfonamides for combating animal pests: The invention relates to 2-cyanobenzene-sulfonamide compounds of the formula (I) where the variables R1 to R5 are as defined in claim 1 and/or to their agriculturally useful salts. Moreover, the present invention relates to the use of compounds (I) and/or their salts for combating animal pests; agricultural compositions comprising such... Agent: Hutchison Law Group PLLC

20070071783 - Pheromone attractants for the green mirid: A pheromone attractant composition for attracting the green mirid, Creontiades dilutus (St{dot over (a)}l), comprising as the component active in attracting green mirids an effective amount of an admixture of hexyl hexanoate and (E)-2-hexenyl hexanoate.... Agent: Moore & Van Allen PLLC

20070071784 - Organic compounds: The invention is directed at a ready-to-use granule bait composition, its preparation and use for the control of house flies inside houses and animal stalls, fodder stores and sanitary installations.... Agent: Novartis Corporate Intellectual Property

20070071785 - Solid stick insecticidal composition: A solid sick insecticidal composition comprising a base, an insecticide and at least 60 wt % food material. The stick may be used to deposit insecticide composition onto a hard surface for controlling crawling insects.... Agent: Merchant & Gould PC

20070071786 - Wax emulsion compositions for attracting insects and methods of using the same: Attractant compositions suitable for attracting fruit flies are described. The compositions are preferably provided in the form of a wax emulsion of the attractant. Both chemical attractants—such as ammonium acetate and ammonium bicarbonate—and food-based attractants—such as protein and yeasts—are described. Insect lures and traps comprising the disclosed compositions are also... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20070071789 - Bioactive material delivery systems comprising sol-gel compositions: Implantable medical devices employing a sol-gel composition coatings that functions as a bioactive material reservoir, and the use of sol-gel composition coatings for improved adhesion of organic and inorganic substrates are disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: C. Rachal Winger

20070071790 - Biodegradable nanocomposites with enhance mechanical properties for soft tissue: The present invention is directed to a novel poly(diol citrates)-based nanocomposite materials created using completely biodegradable and biocompatible polymers that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using nanocomposites comprised of citric acid copolymers and polymers including but not limited... Agent: Marshall, Gerstein & Borun LLP

20070071787 - Composite material comprising a porous semiconductor impregnated with an organic substance: The invention provides a composite material comprising a porous semiconductor impregnated with at least one beneficial organic substance, wherein the beneficial organic substance is present in an amount of at least 15% by weight, based on the weight of the material. Also provided are methods for the preparation of such... Agent: Nixon & Vanderhye, PC

20070071791 - Delivery system for bone growth promoting material: A delivery system that includes a bone growth promoting material encapsulated within a water absorptive gelatinizable covering is used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit within a... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070071788 - Skin integrated device: A skin integrated device for implantation with an improved device-skin interface for the ingrowths of skin cells and tissues throughout the pores, having a solid frame, which may also be permeable. The characteristics of pore size, porosity and size of the compressed and sintered particles constitute a long-term skin integrated... Agent: Mark Pitkin

20070071792 - In vivo formed matrices including natural biodegradale polysaccharides and ophthalmic uses thereof: In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The matrix can also include a bioactive agent that can be released to provide a therapeutic effect to a patient. The formed matrices are particularly... Agent: Kagan Binder, PLLC

20070071793 - Cure for prostate enlargement frequency of urination and cancer: This is a chemical compound designed to eradicate cancer from the prostate (and possibly other parts of the body) restore the prostate to it's normal size, cure frequency of urination and restore urination back to it's youthful state.... Agent: Leon Clark

20070071794 - Drugs for treating diabetes: The present invention provides an agent for recovering insulin secretion function which contains at least one of the amino acids selected from the group consisting of aspartic acid, cystine, serine, asparagine, isoleucine, histidine, hydroxyproline, glutamic acid, valine and salts thereof as an active ingredient; a functional food which contains the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070071795 - Antibodies as growth promoting agents: Animal feed is supplemented with antibody-containing egg powder as a means of improving growth of animals.... Agent: Ade & Company Inc.

20070071796 - Administration form based on cross-linked hydrophilic polymers: The invention relates to a film-shaped administration form for surface administration of at least one active ingredient and/or foodstuff to a living thing. Said administration form comprises at least one layer containing an active ingredient and/or foodstuff, said layer being based on cross-linked hydrophilic polymers and containing 20 wt.-% glycerine... Agent: Frommer Lawrence & Haug

20070071797 - Lotioned fibrous structures: Lotioned fibrous structures and sanitary tissue products comprising such fibrous structures are provided. More particularly, fibrous structures comprising two or more different compositions arranged on a surface of the fibrous structure such that one of the compositions is sandwiched between the fibrous structure surface and the other composition is provided.... Agent: The Procter & Gamble Company Intellectual Property Division

20070071798 - Perforated bioabsorbable oil film and methods for making the same: A bio-absorbable stand-alone film is derived at least in part from fatty acids. The bio-absorbable stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. The stand-alone film has one or more perforations or depressions formed therein. Corresponding... Agent: Lahive & Cockfield, LLP

20070071800 - Acrylic pressure sensitive adhesives: Solution acrylic polymers suitable for dispersing drugs are particularly useful in transdermal drug delivery applications.... Agent: National Starch And Chemical Company

20070071799 - Anchor point for affixing tubes and the like to skin: An Anchor Point is presented for anchoring a tube or the like to the body. The anchors are long lasting and improve patient mobility. In one embodiment the Anchor Point consists of two identical self adhesive flat components. At the proximal end, each Anchor Point component has an interrupted patch... Agent: Chris Tacklind

20070071803 - Dermal penetration enhancers and drug delivery systems involving same: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug... Agent: Foley And Lardner LLP Suite 500

20070071801 - Patch for treating symptoms of a skin abscess: A patch, or bandage for treating skin infections has a backing with pressure-sensitive adhesive for securing on a user's skin in the area of the boil. A liquid absorbent member is positioned in the center of the patch, while a carrier with a medicinal formulation, comprising a menthol solution, surrounds... Agent: Keaty Professional Law Corporation Thomas S. Keaty

20070071802 - Topical anesthetic for dental procedures: A topical anesthetic for dental procedures is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the oral mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight... Agent: Grace J Fishel

20070071804 - Compositions and methods of preparation of liposomal microparticulate il-12: This invention provides methods and compositions for localized delivery of IL-12 to a desired site. The composition comprises liposomes carrying IL-12. The liposomes comprise phosphatidyl choline, phosphatidyl glycerol and cholesterol. The size and composition of the liposomes is such that there is minimal leakage into the systemic circulation. These compositions... Agent: Hodgson Russ LLP

20070071805 - Treatment of inflammation and vascular abnormalities of the eye: Inflammation and vascular abnormalities of the eye, including those related to ischemia, its prophylaxis and its alleviation, are treated by administration to the mammal of small amounts of phosphate-glycerol group presenting bodies such as phosphatidylglycerol liposomes.... Agent: Foley & Lardner LLP

20070071808 - Capsule filled with honey: Capsules containing honey or other sweeteners that may be added to beverages are described. The capsules may be made from a material that dissolves in water or other fluids, or, alternatively, the capsule may be remain intact in a fluid and provide an edible capsule sweetener. The capsule may contain... Agent: Mccarter & English LLP Cityplace I

20070071807 - Capsule-type drug-releasing device and capsule-type drug-releasing device system: A capsule-type drug-releasing device is capable of freely controlling the release and stoppage of a drug and causing neither the back flow of contents of a stomach, an intestine, or the like nor clogging with the contents. A capsule-type drug-releasing device may include: a capsule-shaped casing; a cation exchange membrane... Agent: Seed Intellectual Property Law Group PLLC

20070071806 - Tansmucosal drug delivery system: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in... Agent: Viksnins Harris & Padys Pllp

20070071809 - Ginger containing compositions to control pain: Pain is controlled by ingesting a composition comprising at least about 510 mg of ginger, at least about 1000 mg of glucosamine and at least about 1200 mg of chondroitin sulfate or methylsulfonylmethane, all weights based on a total daily dosage of the composition.... Agent: Whyte Hirschboeck Dudek S C

20070071810 - Additive for tablets: A disintegrant for tablets consisting of an α-1,4-glucan having a degree of polymerization of not less than 180 and less than 1230 and a dispersity (weight average molecular weight “Mw”/number average molecular weight “Mn”) of not more than 1.25 or a modified product thereof. A binder for tablets consisting of... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20070071813 - Novel dosage formulation: wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070071815 - Oral formulation of creatine derivatives and method of manufacturing same: Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt... Agent: Bozicevic, Field & Francis LLP

20070071812 - Pharmaceutical composition containing fenofibrate and method for the preparation thereof: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables... Agent: Buchanan, Ingersoll & Rooney PC

20070071811 - Stable combinations of amlodipine besylate and benazepril hydrochloride: The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.... Agent: Kenyon & Kenyon LLP

20070071814 - Vaginal tablets comprising misoprostol and methods of making and using the same: The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071818 - Effervescent formulations comprising apomorphine: An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine.... Agent: Nixon Peabody LLP - Patent Group

20070071817 - Effervescent oral care compositions and method of use: Solid effervescent compositions are described. The solid compositions include an edible acid and a carbonate salt (e.g., sodium carbonate or sodium bicarbonate). The compositions can further include one or more water soluble functional ingredients. The solid compositions can be free of insoluble particulate material so as to prevent damage to... Agent: Merchant & Gould PC

20070071816 - Oral drug delivery system: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from... Agent: Sughrue Mion, PLLC

20070071819 - Multiple unit modified release compositions of carbamazepine and process for their preparation: The present invention relates to multiple-unit modified release carbamazepine compositions for oral administration which include: (i) at least one extended release unit, and (ii) at least one enteric release unit. Also provided are processes for the preparation of multiple-unit modified release compositions of carbamazepine.... Agent: Ranbaxy Inc.

20070071820 - Delayed release pharmaceutical formulations: Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.... Agent: Duane Morris LLP Patent Department

20070071822 - Film coated tablet for improved upper gastrointestinal tract safety: A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and other tetracyclines/antibiotics, iron preparations, quinidine, nonsteroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline, zidovoudine (AZT), bisphosphonates and mixtures thereof and... Agent: The Procter & Gamble Company Intellectual Property Division

20070071821 - Formulation for providing an enteric coating material: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.... Agent: Fleshner & Kim, LLP

20070071823 - Polyampholytes for delivering polyions to a cell: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to... Agent: Mirus Corporation

20070071824 - Treatment of mucositis using n-acetylcysteine: This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.... Agent: Marsh, Fischmann & Breyfogle LLP

20070071825 - Device and method for making particles: Device for continuously producing particles, consisting of a homogenising compartment (1) including at least one inlet (2) for feeding in an organic phase, an inlet (3) for feeding in an aqueous phase, a mixing system (4) and an outlet (5).... Agent: Nixon & Vanderhye, PC

20070071826 - Method for preparing nano-scale or amorphous particle using solid fat as a solvent: The present invention relates to a method for preparing nanoscale or amorphous particles using solid fat as a solvent. According to the present invention, nanoscale or amorphous particles of active ingredients are prepared by using fat as a solvent, wherein the fat is in solid phase at room temperature. The... Agent: Sheridan Ross PC

20070071827 - Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein: Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also... Agent: Calfee Halter & Griswold, LLP

20070071828 - Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20070071829 - Universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma: A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized... Agent: Jacobson Holman PLLC

20070071830 - Method for increasing bioavailability of lipophilic bioactive compounds: A primary composition that includes at least one lipophilic bioactive compound and a whey protein in an amount effective to increase the bioavailability of the lipophilic bioactive compound, and methods of forming the same. Also, an oral composition that contains the primary composition in a foodstuff, in a food supplement,... Agent: Bell, Boyd & Lloyd LLP

20070071831 - Product for the prevention and the treatment of grapevine infections and method of preparation thereof: A product is described for the prevention and/or treatment of grapevine infections, obtained by the partial or total neutralization of lees originating from winemaking processes, for example by means of alkali or alkali-earth metal oxides or hydroxides; such product generally has a pH comprised between 6.0 and 8.0 and a... Agent: Lucas & Mercanti, LLP

20070071832 - Method for cleaning a lumen: A method and apparatus for removing soil from an inner surface of a lumen wall of a medical instrument are disclosed. A carrier gas entrains particles capable of sublimation at room temperature and transports the particles into and through the lumen. As the particles collide with the soil attached to... Agent: Kusner & Jaffe Highland Place Suite 310

20070071833 - Fungicidal mixtures for controlling rice pathogens: m

20070071835 - Administering pharmaceutical compositions to the mammalian central nervous system: Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be... Agent: Morgan, Lewis & Bockius LLP (sf)

20070071834 - Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method: The present invention discloses a traditional Chinese medicine preparation for cardio-cerebral blood vessel diseases, it is prepared through extracting danshen and Notoginseng by lye, precipitating with alcohol, concentrating, and adding other medicine and excipients. Then using the HAPLY-MS and HAPLY fingerprint Atlas to characterize its Physicochemical properties completely. Using the... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070071836 - Transfer factor preparations and associated methods: A drink includes an edible liquid or semisolid preparation and transfer factor. The drink may also include lactoferrin and one or more preservatives. An edible preparation includes a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin-containing fruit. The edible preparation may also include lactoferrin.... Agent: Trask Britt

20070071837 - Treatment of aspirin resistance with radix salviae mitiorhizae, its extract and composition: The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).... Agent: Harness, Dickey & Pierce, P.L.C

20070071838 - Method for the treatment of cachexia: A pharmaceutically acceptable salt of perindopril of formula (I) is made from a protected precursor compound of formula (II) wherein R represents a carboxyl protecting group, which process comprises subjecting a compound of formula (II) to deprotection of the carboxylic group COOR attached to the heterocyclic ring so as to... Agent: Knoble, Yoshida & Dunleavy

20070071839 - Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne: The present invention relates to topical compositions containing: a) Ginkgo biloba terpenes; b) floroglucinols pure or in mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract; for the treatment of atopic dermatitis, skin allergic conditions and acne.... Agent: Young & Thompson

20070071840 - Method for treatment of cartilage disorders with centella extract: The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of Centella extract. The composition is delivered locally by parenteral administration to... Agent: Philip S. Johnson Johnson & Johnson

20070071841 - Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome: The present invention relates to a method of preventing and/or treating Metabolic Syndrome and/or the conditions that comprise Metabolic Syndrome by administering to a mammal, including a human, a dietary supplement comprising grape extract. This invention also relates to a method of treating and/or preventing pre-hypertension by administering to a... Agent: Kenyon & Kenyon LLP

20070065359 - Nanocells for diagnosis and treatment of diseases and disorders: The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20070065360 - Nonpolar thymidine analogs: e

20070065361 - Ligands to radiation-induced molecules: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070065362 - Gastrin receptor-avid peptide conjugates: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject... Agent: Kohn & Associates PLLC

20070065363 - Quantifying hemodynamic response to drug therapy using implantable sensor: Systems and methods provide for assessing a patient's hemodynamic response to a drug therapy. A patient's hemodynamic response to a drug therapy is monitored using sensor data acquired using one or more sensors. The patient's hemodynamic response to the drug therapy is quantified, such as by quantifying a patient's sensitivity... Agent: Hollingsworth & Funk, LLC

20070065365 - Abuse-resistant transdermal system: An abuse-resistant transdermal system which contains, in addition to one or more active ingredients with potential for abuse, at least one gel-forming agent in quantities such that it forms a gel with a minimum quantity of an aqueous liquid, and contains as further agents which complicate or prevent abuse at... Agent: Crowell & Moring LLP Intellectual Property Group

20070065364 - Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same: The present invention relates to co-extruded pharmaceutical compositions and dosage forms comprising an adverse agent, such as an opioid antagonist, which can be sequestered. The pharmaceutical compositions and dosage forms diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to... Agent: Duane Morris LLP Patent Department

20070065366 - Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation: The invention relates to a liquid, propellant-free pharmaceutical formulation in the form of ready-to-use preparation for administration by nebulisation comprising a water soluble salt of the beta2-agonist 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone as active ingredient. The active ingredient is chemically stable in the formulation, and said formulation is provided of an adequate shelf-life suitable... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065368 - Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including... Agent: Michelle Lecointe Baker Botts L.L.P.

20070065367 - Method of treating pulmonary disease with interferons: A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.... Agent: Klauber & Jackson

20070065369 - Novel methods and composition for delivering macromolecules to or via the respiratory tract: A composition comprises a lipid-based microstructure with at least one bioactive macromolecule. The composition provides improved bioavailability and is capable of rapidly releasing a bioactive macromolecule. It is believed that the improved bioavailability is due, at least in part, to the reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance.... Agent: Nektar Therapeutics

20070065370 - Suspension aerosol formulationis of pharmaceutical products: Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070065373 - Mucoactive agents for treating a pulmonary disease: The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It... Agent: Davidson, Davidson & Kappel, LLC

20070065374 - Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations: Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070065371 - Novel dry powder inhalation system for transpulmonary administration: The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the present invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition prepared by freeze-drying a composition liquid containing ingredients in a non-dissolved form, and has:... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070065372 - Process for the production of particles: A process for the production of particles comprises the steps of formation of a solution of a desired substance in a suitable solvent; ii)generation of an aerosol from the solution of said substance; iii) collection of the aerosol droplets in a vessel containing a non-solvent of said substance; and iv)... Agent: Bell & Associates

20070065375 - Oral composition comprising micron-sized lanthanide metal oxide: Oral composition comprising as abrasive a mixture of a lanthanide metal oxide and a further abrasive, characterised in that the lanthanide metal oxide has a weight average particle size of from 0.5 to 50 ÿm.... Agent: Unilever Intellectual Property Group

20070065376 - Method and composition for preventing tooth hypersensitivity when using passive bleaching agents: Dental bleaching compositions, for example in the form of liquids, gels, creams, pastes and ointments, comprising a peroxide releasing compound and from 1% to 35% by weight of a potassium-containing compound such as potassium nitrate, wherein the potassium nitrate is present in a safe and effective amount to prevent tooth... Agent: Salter & Michaelson The Heritage Building

20070065377 - Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same: The present invention relates to a composition for promoting collagen synthesis and a composition for external application to skin which includes the collagen synthesis promoting composition. The collagen synthesis promoting composition includes, as an effective component, at least one selected from the group consisting of compounds represented as: wherein R... Agent: Ladas & Parry

20070065379 - Microcapsules having an aqueous core and their use in cosmetics: Microcapsules containing a polymeric and/or waxy envelope encapsulating an aqueous medium containing an acrylic polymer containing a phosphorylcholine group. Composition containing these microcapsules. Application to, caring for, and to making up keratinous substances.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065378 - Sunscreen compositions: A composition and method for enhancing the SPF value of UV absorbing agents which are formulated into sunscreen composition and applied to the skin is disclosed. A mixture is formed which includes at least one UV absorbing agent and an effective amount of a dimethicone copolyol wax composition. The composition... Agent: Legal Department Noveon, Inc.

20070065380 - 2-o-(beta-d-glucopyranosyl) ascorbic acid, process for its production, and foods cosmetics containing compositions comprising it: The composition comprising the novel compound 2-O-(β-D-glucopyranosyl)ascorbic acid has been extracted from plants such as from Ningxia Lycium barbarum L. and/or Lycium chinense Mill. The compositions comprising 2-O-(β-D-glucopyranosyl)ascorbic acid may be enzymatically synthesized using β-D-glucosyltransferase. Pure 2-O-(β-D-glucopyranosyl)ascorbic acid may be produced from such compositions. Alternatively, 2-O-(β-D-glucopyranosyl)ascorbic acid may be produced... Agent: Drinker Biddle & Reath (dc)

20070065382 - Cosmetic composition comprising at least one active agent and particles containing at least one colored inorganic pigment in a matrix, and skincare use thereof: Disclosed herein is a cosmetic composition for treating and/or caring for the skin, which comprises, in a physiologically acceptable medium, at least one cosmetic active agent and at least one colored particle comprising at least one inorganic pigment arranged inside a matrix, wherein the composition has an opacity of less... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070065381 - Skin care composition: Skin care composition comprising a plurality of interference pigments and a dermatologically acceptable carrier. The plurality comprises at least a first interference pigment which reflects a first color, and at least a second interference pigment which reflects a second, complementary color. The total amount of interference pigments is from about... Agent: The Procter & Gamble Company Intellectual Property Division

20070065383 - High alcohol content foaming compositions with silicone-based surfactants: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise a C1-4 alcohol, (>40% v/v), a silicone-based surfactant of at... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070065384 - Hygienic and cosmetic compositions for treating atopical dermatites: A series of hygienic cosmetic products which, without a particular pharmacological activity, are adapted to be used according to a differentiated functional and specific use, on skins having symtoms related to atopic dermatitis, are herein disclosed. The compositions reduce pruriginous feelings and related scratching stimulation, while holding a proper physiologic... Agent: Hedman & Costigan P.C.

20070065385 - Cold production method for pearly lustre preparations containing alcohols: Compositions and methods are disclosed for producing pearlized compositions of alcoholic hydrogels at ambient temperatures. More particularly, compositions and methods are disclosed for pearlized alcoholic hydrogel compositions with stearyl alcohol at preparation temperatures below the melting point of stearyl alcohol, which is solid at room temperature. Pearlizing effects are achieved... Agent: Clariant Corporation Intellectual Property Department

20070065388 - Disinfectant gel for hands: The invention provides a quick-drying disinfectant gel for hands that spreads well in rubbing into hands, spreads easily over the hands, forms no scum, and is not sticky before and after drying. The disinfectant gel for hands of the invention contains 0.01 to 2.0 wt % of a maleic anhydride... Agent: Sughrue Mion, PLLC

20070065389 - Genes from chromosomes 3, 5 and 11 involved in premature canities: The disclosure provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 3 selected from KIAA1042,... Agent: Buchanan, Ingersoll & Rooney PC

20070065387 - Method for enhancing the effect of particulate benefit agents: A method for applying a particulate benefit agent to a body surface is provided. The method employs a particulate benefit agent coated with a polymer. The polymer-coated benefit agent is applied to a body surface such as hair or skin, in the presence of a composition comprising a peptide having... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070065386 - Use of oligosaccharides in cosmetic, food or dermatological compositions for stimulating the differentiation of epidermal cell: The present invention related to a method for preventing or treating skin disorders comprising administering to a subject a dermatological composition comprising oligogalacturonides.... Agent: Bachman & Lapointe, P.C.

20070065390 - Stable emulsion systems with high salt tolerance: A salt-tolerant, stable emulsion system having low viscosity, as well as method of making the same, is disclosed. The emulsion system may be used for cosmetic and dermatological applications and provides unique benefits.... Agent: Fitzpatrick Cella Harper & Scinto

20070065391 - C10 alkanolalkoxylate mixtures and use thereof as novel low-foaming wetting agents: s

20070065392 - Cosmetic composition with an amphiphilic lipid phase: or a salt, solvate, or isomer thereof, wherein R1, R2, R3, and R4 each independently represent a hydrogen atom, a C1-C4 alkyl group, or a C2-C6 hydroxyalkyl group that includes from 1 to 5 hydroxyl groups, wherein at least one of the radicals R1 to R4 represents a hydroxyalkyl group,... Agent: Oliff & Berridge, PLC

20070065393 - Make-up-removing composition: An aqueous make-up-removing composition containing a derivative (product) of polyethylene glycol and a mixture of glycerides of caprylic acid and of capric acid comprising 7 ethylene oxide groups. The composition can constitute a make-up-removing water which is very comfortable to the eyes, used in particular for removing make-up gently from... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065394 - Compositions effective in altering the perception of malodor: A method of modifying perception of a malodor, such as the stench associated with putrefying flesh, by selectively affecting specific olfactory receptors in an individual is disclosed. Disclosed are articles of manufacture and especially innovative compositions effective in implementing the method of the present invention including at least three plant... Agent: Martin D Moynihan Prtsi Inc

20070065395 - Topical compositions containing plant extracts for personal care: A topical composition or a personal beauty care product (e.g., soap, shampoo, rinse, hair conditioner, and the like) comprises chemical or biological substances or plant extracts obtained from certain plants, in particular, plant species of the family Liliaceae or Amaryllidaceae, preferably selected from the following Allium species such as Allium... Agent: St. Onge Steward Johnston & Reens, LLC

20070065396 - Topical macqui berry formulation: The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a... Agent: Darby & Darby P.C.

20070065397 - Material having deodorizing function and process for production thereof: A material having a deodorizing function, characterized in that it comprises a paper powder containing a copper or zinc compound or copper and zinc compounds retained therein. A method for producing a material having a deodorizing function, characterized in that it comprises mixing an aqueous solution of a copper or... Agent: Ostrolenk Faber Gerb & Soffen

20070065398 - Photoactivatable composition and uses thereof: The invention relates to a photoactivatable compound having a support molecule chosen from carbon-containing and/or sulfur-containing and/or nitrogen-containing and/or phosphorus-containing nonpolymer compounds, polymers and oligomers and to which are covalently bonded at least two species containing chemical groups which, after irradiation between 200 and 450 nm, are converted into reactive... Agent: Steptoe & Johnson LLP

20070065406 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065401 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065402 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065400 - Treatment of tumor metastases and cancer: Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070065399 - Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules: The present invention provides methods that utilize compositions containing colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, as modulators of intracellular signaling molecules, for example.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070065403 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065405 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065404 - Uses of humans zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070065407 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070065408 - Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b: This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070065410 - Peptides binding the phosphatase 2a protein and polynucleotides encoding same: The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065412 - Production of recombinant aav using adenovirus comprising aav rep/cap genes: This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA inert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or... Agent: Morrison & Foerster LLP

20070065411 - Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.... Agent: Fulbright & Jaworski L.L.P.

20070065409 - Use of pleiotrophin in the diagnosis, treatment and prevention of disease: Described herein are methods for transdifferentiating monocytes/macrophages into endothelial cells, based on the inventors' identification of pleiotrophin (“PTN”) as the gene responsible for this transdifferentiation. Further described are therapeutic methodologies for the promotion or inhibition of neovasculanization based on modulation of PTN.... Agent: Davis Wright Tremaine LLP

20070065421 - Inducing expression of puma to reduce joint inflammation in the treatment of arthritis: It has been discovered the BH3-only proapoptotic Bcl-2 proteins like PUMA (the p53 upregulated modulator of apoptosis) can be activated in fibroblast-like synoviocytes present in the joints of subjects with rheumatoid arthritis. This bypasses the p53 apoptotic pathway, which normally clears FLS fomr the joints, but is often defective in... Agent: Dla Piper US LLP

20070065422 - Induction of immune tolerance by sertoli cells: The subject invention pertains to methods to enhance the therapeutic effects of cell therapy in various diseases and disorders. More particularly, the present invention provides methods of inducing systemic immune tolerance, thereby reducing or eliminating the need for systemic immunosuppression, by administering isolated Sertoli cells to an individual in need... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070065423 - Antidiarrheal agent for livestock and poultry: The present invention is to provide a safe antidiarrheal agent and a method for suppressing diarrhea by which an efficient antidiarrheal effect is achieved without using antibiotics or synthetic antibacterial agents that have been conventionally used against infections in livestock and poultry. Antibiotic-resistant pathogenic infections an also invented aid treated... Agent: Frommer Lawrence & Haug

20070065413 - Livestock anti-acid composition: Acid compositions for ruminants containing a plurality of acid-neutralizing salts with pKa's effective at different ruminant gastrointestinal pH ranges and an active probiotic culture capable of stimulating the growth and concentration of beneficial acid-consuming rumen microorganisms. Methods for preventing clinical and sub-clinical acidosis in ruminants with the acid-neutralizing salts and... Agent: Synnestvedt Lechner & Woodbridge LLP

20070065415 - Compositions and methods for the augmentation and repair of defects in tissue: Compositions and methods of treating a defect in a patient are disclosed, including expanding a culture of autologous cells in vitro to form cultured cells, collecting the cultured cells for introduction into the patient, and depositing the cultured cells with ancillary proteins.... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070065414 - Enhanced delivery of cells: The present invention provides a method comprising administering cells by infusion through a blood vessel and administering a vasodilator, a vascular enhancer, or both. In accordance with one embodiment, the delivery of stem cells to the myocardium by intracoronary infusion is improved by administration of one or more vasodilators and/or... Agent: Kenyon & Kenyon LLP

20070065419 - Keratinocytes useful for the treatment of wounds: The invention relates to new keratinocytes which may be cultured in vitro and the advantageous use thereof for preparing a product which can be used to treat acute and chronic wounds.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070065418 - Method and device for cellular therapy: A device and method for performing a therapeutic treatment at a treatment site in a patient's vessel, the device configured to be introduced by means of a catheter, the device including an expandable portion capable of being expanded between a contracted position and a deployed position at the treatment site,... Agent: Popovich, Wiles & O'connell, PA 650 Third Avenue South

20070065416 - Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070065417 - Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070065420 - Ultrasound therapy resulting in bone marrow rejuvenation: A method and system for treating a patient to repair damaged tissue which includes exposing a selected area of bone marrow of a patient to ultrasound waves or ultra shock waves so that cells comprising stem cells, progenitor cells or macrophages are generated in the area of the bone marrow... Agent: Wilson Daniel Swayze, Jr.

20070065424 - Rationally designed polysaccharide lyases derived from chondroitinase b: The invention relates to rationally designed polysaccharide lyases and uses thereof. In particular, the invention relates to modified chondroitinase B. The modified chondroitinase B enzymes of the invention are useful for a variety of purposes, including cleaving and sequencing polysaccharides such as glycosaminoglycans (GAGs) as well as removing polysaccharides from... Agent: Wolf Greenfield & Sacks, PC

20070065425 - Anti-idiotypic antibody neutralizing the inhibitor activity of a factor viii inhibitor antibody: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its... Agent: Birch Stewart Kolasch & Birch

20070065427 - Agents that modulate immune cell activation and methods of use thereof: Disclosed are methods for identifying an agent that modulates an immune response. One such method comprises screening for agents which inhibit the interaction between a PD-1 ligand and a PD-1 polypeptide, and determining whether the agents inhibit the interaction between a PD-1 ligand and a B7 polypeptide, to identify an... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070065428 - Early b-cell detection for selecting vaccines: The present invention discloses an affinity-binding assay comprising a particle having at least four copies of a target molecule and at least two binding molecules specific for the target molecule, wherein a first of the binding molecules is associated with a first label and a second of the binding molecules... Agent: Trask Britt

20070065426 - Tumor necrosis factor binding ligands: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of... Agent: Morrison & Foerster LLP

20070065432 - Antibody fragment-targeted immunoliposomes for systemic gene delivery: A targeted vector allowing enhanced gene transfer to human hepato-cellular carcinoma (HCC1) cells in vitro was developed using cationic liposomes covalently conjugated with the mAb AF-20. This high affinity antibody recognizes a rapidly internalized 180 kDa cell surface glycoprotein which is abundantly expressed on the surface of human HCC and... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070065430 - Nogo-a neutralising immunoglobulins for treatment of neurological diseases: The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070065429 - Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques: The invention provides methods for treating diseases involving aberrant amyloid-β (Aβ) peptide deposition, including Alzheimer's Disease, by the administration of Nogo receptor antagonists. The invention also provides method for reducing levels of Aβ peptide in a mammal by the administration of soluble Nogo receptor polypeptides... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070065431 - V-like domain binding molecules: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the... Agent: Frommer Lawrence & Haug

20070065437 - Anti-cd3 antibody formulations: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070065436 - Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies: Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070065434 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070065435 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070065433 - Methods and compositions for the treatment of meconium aspiration syndrome: A method for preventing or treating meconium aspiration syndrome (“MAS”) by administering a meconium aspiration syndrome preventing or treating amount of one or more complement inhibitors to a patient likely to develop or suffering from MAS. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved... Agent: Hunton & Williams LLP Intellectual Property Department

20070065438 - Methods of inducing and maintaining immune tolerance: Provided are methods of enhancing and maintaining immune tolerance by modulation of CD200 or CD200R. Provided are antagonists thereof including antibodies.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070065439 - Antibodies against interleukin-1 beta: Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the... Agent: Knobbe Martens Olson & Bear LLP

20070065440 - Antibody compositions and methods: Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070065442 - Compositions and methods for treating hyperimmune response in the eye: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070065441 - Human pf4a receptors, nucleic acid encoding and antibodies binding thereto: cDNAs encoding a class of receptors, including the IL-8 receptor, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory... Agent: Genentech, Inc.

20070065443 - Fructoseamine 3 kinase and the formation of collagen and elastin: The invention relates to the discovery that levels of collagen and elastin can be modulated by changing the flux through the Amadori Pathway and that copper containing compounds and complexes inhibit the enzyme fructoseamine-3-kinase.... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath

20070065444 - Human monoclonal antibodies to activin receptor-like kinase-1: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070065445 - Novel cyclooxygenase variants and methods of use: The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene... Agent: Howrey LLP

20070065446 - Anti-bambi antibody and diagnostic or remedy for colon cancer and liver cancer: The present invention provides an antibody (anti-BAMBI antibody) which recognizes a polypeptide having the amino acid sequence of SEQ ID No: 1 or a polypeptide having an amino acid sequence containing deletion, substitution or addition of one or more amino acids as compared to the amino acid sequence of SEQ... Agent: Jones Day

20070065451 - Enhancement of intracellular delivery and tissue targeting of drugs and genes: A method for enhancing intracellular delivery of effector molecules is provided. The method involves modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target specifically recognized by the antibody.... Agent: Licata & Tyrrell P.C.

20070065447 - Laminin-5 gamma2-binding peptides, related compositions, and use thereof: Novel peptides that specifically bind the γ2 chain of laminin-5 and other γ2-associated proteins; related compositions (e.g., derivatives and variants of such peptides; nucleic acids comprising sequences encoding such peptides; pharmaceutical compositions comprising either of such molecules; etc.); methods of using the same for diagnostic, prophylactic, and therapeutic purposes; and... Agent: Novo Nordisk, Inc. Patent Department

20070065449 - Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-vegf therapy (bevacizumab): The present invention relates to a pharmaceutical cocktail, in particular, effective amounts of gemcitabine, in combination with effective amounts of docetaxel and angiogenesis inhibitor, especially a vascular endothelial growth factor (VEGF) inhibitor, such as bevacizumab for the treatment of cancer, in particular sarcoma, especially soft tissue sarcoma. Pharmaceutical compositions and... Agent: Coleman Sudol Sapone, P.C.

20070065448 - Methods and compositions for treating diseases targeting maba1: Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro.... Agent: Celera Genomics Attn: Wayne Montgomery, Vice Pres, Intel Property

20070065450 - Snail, a new marker for tumour invasion and target protein of new antitumoral compounds: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of... Agent: Dann, Dorfman, Herrell & Skillman

20070065452 - Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases: The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to... Agent: Alston & Bird LLP

20070065453 - Transferrin-binding proteins from neisseria gonorrhoeae and neisseria meningitidis: Iron-regulated, outer membrane proteins found in Neisseria gonorrhoeae and Neisseria meningitidis are important in transferrin receptor function. The proteins, which are isolatable by means of a transferrin affinity column, bind specifically to antisera raised against an iron-regulated outer membrane protein having a molecular weight of approximately 100 kD found in... Agent: Kenyon & Kenyon LLP

20070065454 - Liposomal vaccine: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.... Agent: White & Case LLP Patent Department

20070065455 - Eta-1 gene and methods for use: The present application relates to osteopontin (Eta-1) polypeptides, nucleic acids that encode Eta-1, antibodies that specifically bind to Eta-1, and methods for enhancing an immune response in an animal.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070065456 - Nutritional supplements: Nutritional supplement formulations are disclosed, such as nutritional supplement formulations that include Wasabia japonica. Methods for using the same to supplement a human diet are also disclosed.... Agent: Fish & Richardson P.C.

20070065457 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070065459 - Pharmaceutical compositions for treating papillomavirus tumors and infection: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of... Agent: Buchanan, Ingersoll & Rooney PC

20070065458 - Vaccine compositions comprising streptococcus pneumoniae polypeptides having selected structural motifs: A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan,

20070065461 - Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni: An immunogenic composition, and method of using the composition, composed of a capsule polysaccharide polymer from one or more strains Campylobacter jejuni. The composition is either used alone or is conjugated to a carrier molecule, such as CRM197. An aspect of the invention is that the immunogenic composition induces an... Agent: Naval Medical Research Center Attn: (code 00l)

20070065460 - Process for producing a capsular polysaccharide for use in conjugate vaccines: A method for producing a polysaccharide and a conjugate vaccine including the polysaccharide produced according to the method. A characteristic step in the method is that the pH of the culture medium is kept at a constant value with base or acid until adjustment with respectively base or acid is... Agent: Young & Thompson

20070065462 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached... Agent: Sanofi Pasteur, Inc.

20070065463 - Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions: The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations... Agent: Davidson, Davidson & Kappel, LLC

20070065465 - Conjugate vaccines for the prevention of dental caries: The present invention provides glucan-based compositions and methods for stimulating an immune response against mutans streptococci components and vaccines and methods for the treatment and prevention of dental caries. In a preferred embodiment, a glucan polymer, preferably WSG, is covalently bound to one or more T cell-dependent antigens to form... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070065464 - Immunogenic compositions for streptococcus pyogenes: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS... Agent: Novartis Vaccines And Diagnostics Inc.

20070065466 - Clostridium difficile vaccine: A vaccine for the treatment or prophylaxis of C. difficile associated disease comprises a C. difficile gene or a C. difficile peptide/polypeptide or a derivative or fragment or mutant or variant thereof which is immunogenic in humans. The gene encodes a C. difficile surface layer protein, SlpA or variant or... Agent: Jacobson Holman PLLC

20070065468 - Chimeric allergens for immunotherapy: The present invention provides a chimeric polypeptide for reducing specific IgE binding to at least two house dust mite allergens in a subject, said chimeric polypeptide comprises an amino acid sequence comprising sequences of said at least two house dust mite allergens and wherein upon exposure to said allergens, said... Agent: Morrison & Foerster LLP

20070065467 - Immunostimulatory nucleic acid molecules for activating dendritic cells: The present invention relates generally to methods and products for activating dendritic cells. In particular, the invention relates to oligonucleotides which have a specific sequence including at least one unmethylated CpG dinucleotide which are useful for activating dendritic cells. The methods are useful for in vitro, ex-vivo, and in vivo... Agent: Wolf Greenfield & Sacks, PC

20070065469 - Liquid formulations with high concentration of human growth hormone (high) comprising glycine: The present invention relates to liquid formulations of human growth hormone (hGH, somatropin) which are storage stable, show reduced or no crystallization on storage and are suitable for administration to the human or animal body. More particularly, the invention relates to liquid formulations of human growth hormone which are stable... Agent: Novartis Corporate Intellectual Property

20070065472 - Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers: are useful active agents for inducing and/or stimulating the growth of mammalian keratin fibers and/or reducing the loss and/or increasing the density thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for caring for or making up the hair or the... Agent: Buchanan, Ingersoll & Rooney PC

20070065471 - Cosmetic/dermatological applications of ppar receptor activators: Cosmetic/pharmaceutical compositions useful for regulating the size of sebaceous glands and, in particular, for inhibiting sebum production, or for treating pathologies entailing an overproduction of sebum, or for treating greasy skin and/or a scalp prone to dandruff, contain thus effective amounts of at least one activator of PPAR type receptors.... Agent: Buchanan, Ingersoll & Rooney PC

20070065473 - Nitric oxide gas (go) as a cosmetic and wound healing agent: The present invention provides a method and device for exposing injured mammalian tissues, in a non-abrasive manner, to an effective amount of exogenous gaseous nitric oxide (gNO) in order to promote healing by reducing the size, duration and severity of wounds as well as controlling the infection by reducing number... Agent: Sidley Austin Brown & Wood LLP (laip Group)

20070065470 - Oleaginous composition containing a flowable active ingredient: Described is an oleaginous composition containing an especially antioxidative, flowable active ingredient, said composition being used as an additive for an oil principally for food preparations, wherein the viscosity of the composition is between the viscosity of the active ingredient and the viscosity of the oil.... Agent: Jacobson Holman PLLC

20070065475 - Methods and compositions for antimicrobial surfaces: The present invention comprises methods and compositions for treating solid surfaces having antimicrobial and biocidal properties. Such surfaces are capable of controlling or killing a broad spectrum of biological agents, including viruses, bacteria and other microbial agents in solids, liquids or gases that subsequently contact the treated surface.... Agent: Troutman Sanders LLP

20070065474 - Topical gel formulation comprising organophosphate insecticide and its preparation thereof: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20070065476 - Pest control agent carrier: A formulation for the control of arthropod pests comprising one or more hydrophobic or non-polar semiochemicals, water, a thickener and a rubber crumb carrier. The formulation may also include additives such as a feeding stimulant or bait, toxicant or insecticide, anti-microbial agent, humectant, volatility suppressant, pigment and an anti-oxidant. The... Agent: Buckingham Doolittle & Burroughs

20070065480 - Block copolymers of acrylates and methacrylates with fluoroalkenes: A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device.... Agent: Squire, Sanders & Dempsey LLP

20070065477 - Composition, system, and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility: An implantable drug delivery device loaded with a beneficial agent is provided, wherein the beneficial agent is in two different forms, a first form having a higher solubility and a second form having a lower solubility, and wherein the two different forms are present in a proportion which is selected... Agent: Cindy A. Lynch Conor Medsystems, Inc.

20070065478 - Polycationic peptides for cardiovascular therapy: Coatings for implantable medical devices and methods for fabricating the same are disclosed. The coating includes polycationic peptides, for example R7.... Agent: Squire, Sanders & Dempsey LLP

20070065479 - Therapeutic composition and a method of coating implantable medical devices: A method of making a therapeutic composition, as well as the therapeutic composition so made, is disclosed. The method comprises mixing a hydrophobic drug with an aqueous buffer solution and adding a surfactant to the aqueous buffer solution to form the therapeutic composition. A implantable medical device with the therapeutic... Agent: Squire, Sanders & Dempsey LLP

20070065482 - Articles including natural biodegradable polysaccharides and uses thereof: Medical articles having a body member including natural biodegradable polysaccharides are described. The body member is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The body member can also include a bioactive agent which can be released to provide a therapeutic effect to a patient.... Agent: Kagan Binder, PLLC

20070065481 - Coatings including natural biodegradable polysaccharides and uses thereof: Biodegradable coatings and articles that include natural biodegradable polysaccharides are described. The coatings and articles are formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups.... Agent: Paul Weaver Kagan Binder PLLC

20070065484 - In situ occlusion using natural biodegradable polysaccharides: In situ formed biodegradable occlusions including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups.... Agent: Kagan Binder, PLLC

20070065483 - In vivo formed matrices including natural biodegradable polysaccharides and uses thereof: In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The matrix can also include a bioactive agent which can be released to provide a therapeutic effect to a patient.... Agent: Kagan Binder, PLLC Maple Island Building

20070065485 - Therapeutic delivery of carbon monoxide: Boranocarbonates are described for administration to a human or other mammal for delivery of carbon monoxide. The boranocarbonate is a compound or ion adapted to make CO available for physiological effect, and may be administered with a guanylate cyclase stimulant or stabilizer. The physiological effect may be stimulation of neurotransmission,... Agent: Nixon & Vanderhye, PC

20070065488 - Food composition having anti-stress action: Food compositions which comprise, as an active ingredient, an extract of migratory fish or a mixture of nutritional components of a similar composition to the above-mentioned extract in an amount of 0.5 g or more per one meal of the extract or the mixture in terms of the solid content... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065486 - Migraine remedy: The invention relates to uses and methods of treating migraine with a plant extract that includes a therapeutically effective dose of a mixture of flavonoids rich in proanthocyanidis. Methods and uses are described to substantially prevent migraine from occurring; reduce the frequency of migraine or reduce the severity of migraine... Agent: Townsend And Townsend And Crew, LLP

20070065487 - Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof: A colloidal crystalline solution comprising a xanthophyll ester having a high trans-lutein content and at least one oil is provided. The solution may be prepared by dissolving the xanthophyll ester in the oil. Methods of using the solution are also provided.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065491 - Devices and methods for the delivery of blood clotting materials to bleeding wounds: An apparatus for promoting the clotting of blood and controlling bleeding comprises a receptacle for retaining blood clotting material in particulate form therein. A pad for controlling bleeding comprises a mesh structure and a support attached to the mesh structure to facilitate the application of pressure to the pad and... Agent: Michaud-duffy Group LLP

20070065489 - Hair holder: A hair holder (1) composed of two hair holding sheets (3) for holding a hair bundle in a prescribed shape. The hair holding sheet (3) is an agent-impregnated sheet (3a) having a Taber stiffness of 0.2 mN·m or higher and a water retention of 0.03 g/cm2 or more and impregnated... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065490 - Substrates and compounds bonded thereto: Immobilization substrates and tethering compounds compatible with such substrates are described. In one aspect, the invention provides an article comprising: a substrate having a first surface and a second surface; a triazine tethering group affixed to the first surface of the substrate, the triazine tethering group comprising a reaction product... Agent: 3m Innovative Properties Company

20070065492 - Cladribine formulations for improved oral and transmucosal delivery: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.... Agent: Buchanan, Ingersoll & Rooney PC

20070065496 - Dermal therapeutic system comprising 2-(3-benzophenyl)propionic acid: The invention relates to a dermal therapeutic system having a cover layer, an adhesive matrix having a content of, as active ingredient, 2-(3-benzophenyl)propionic acid or [o-(2,6-dichloroanilino)phenyl]acetic acid or a derivative thereof customary in pharmacy, and a removable protective layer, characterised in that the adhesive matrix is an acrylate copolymer adhesive... Agent: King & Spalding LLP

20070065493 - External patch containing estrogen and/or progestogen: An external patch capable of stable prolonged release and transdermal absorption of active ingredient hormones (estrogens and/or progestogens) contained in a pressure sensitive adhesive layer, which external patch ensures low irritation on the skin. In particular, an external patch comprising a support and, superimposed thereon, a pressure sensitive adhesive layer,... Agent: Ostrager Chong Flaherty & Broitman PC

20070065494 - Formulations and methods for enhancing the transdermal penetration of a drug: Methods and formulations of enhancing the permeability the skin of a subject to a drug are disclosed. The method may include administering a combination of lauryl alcohol and isopropyl myristate as a penetration enhancer to the area of skin to provide synergistically enhanced penetration of the drug.... Agent: Thorpe North & Western

20070065495 - Transdermal hormone delivery system: compositions and methods: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070065497 - Combination and method using edta combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-plate: The invention is for the combination of EDTA and glutathione in the reduced state encapsulated in a liposome for prevention and therapy of coronary artery disease (CAD), and anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal. The combination is particularly... Agent: Brooke Schumm Iii

20070065498 - Encapsulated arsenic drugs: The present invention relates to methods and compositions for the treatment of cancer and for research and analysis of cancer. In particular, the present invention provides encapsulated arsenic anti-cancer compositions with improved properties.... Agent: Medlen & Carroll, LLP Suite 350

20070065499 - Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof: The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex;... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070065501 - Method for banding hard capsules using hydroxypropylmethyl cellulose (hpmc) as a base: The present invention provides a banding composition for hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base comprising (1) low viscosity HPMC; (2) a component selected from the group consisting of methanol, ethanol, isopropanol, 1-propanol, acetone and/or ethyl acetate; (3) a surfactant; and (4) water; and a method for banding... Agent: Rosemary M. Miano Attorney For Applicant

20070065502 - Methods and apparatus for sealing capsules: Methods and apparatus for providing a leak-proof seal for two-piece capsules containing oil-based liquids or other compositions by a two-stage process. The capsule cap and capsule body are combined by a nitrogen purge instant bonding (NPIB) system. An overlay medium is applied to selected portions of the capsule, including near... Agent: Edward C. Schewe

20070065500 - Northern white kidney bean extract and red kidney bean extract in combination with green tea extract in the treatment of obesity: The present invention is for composition containing extract of Northern White Kidney Bean (Phaseolus vulgaris), extract of Red Kidney Bean (Locust Bean Gum) (Ceratonia siliqua) and extract of Green Tea (Camellia Sinensis). This invention as a supplemental compound, aids in weight reduction both in overweight and obese individuals. This invention... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070065503 - Active substance-doped absorbing polymer particles, composition comprising polycondensate matrix and absorbant polymer for release of a wound treatment substance: A water-absorbing composition, a process for producing a water-absorbing composition, a composite comprising a water-absorbing composition, and the use of a water-absorbing composition for releasing an active substance (e.g., a wound treatment substance, a care substance, or combinations thereof) are disclosed. A water-absorbing composition can include active substance-doped water-absorbing polymer... Agent: Smith Moore LLP

20070065504 - Products and methods for treating vaginal infections: The methods of the invention treat vaginal fungal and yeast infections. More particularly, according to the methods of the invention, solid dosage forms may be administered to patients to treat vaginal fungal and yeast infections subsequent to awakening at any time during the day more than thirty minutes prior to... Agent: Philip S. Johnson Johnson & Johnson

20070065507 - Bisphosphonate formulation: A bisphosphonate for treatment of osteoporosis is formulated with an amount of an antifoaming agent effective for reducing foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070065508 - Composition comprising vitamin b12 and acid reducing agent and uses thereof: The present invention provides compositions and methods for treating or reducing the risk of a vitamin B12 deficiency in a subject having or in need of a gastrointestinal acid reduction treatment.... Agent: Faegre & Benson LLP Patent Docketing

20070065506 - Keratin and soluble derivatives thereof for a nutraceutical and to reduce oxidative stress and to reduce inflammation and to promote skin health: Keratin and derivatives thereof, preferably S-sulfonated keratin intermediate filament protein, S-sulfonated keratin high sulfur protein, and S-sulfonated peptides provide antioxidant activity, e.g., that equal to 200-2200 μmol TEAC/100 g or 100 ml, and are useful in an oral supplement to cause reduction in oxidative stress and benefits stemming therefrom, e.g.,... Agent: Bacon & Thomas, PLLC

20070065509 - Method of preparing sustained-release preparations of quinolone antibiotics: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.... Agent: Banner & Witcoff

20070065505 - Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the... Agent: Novartis Corporate Intellectual Property

20070065511 - Controlled delivery creatine formulations and method of using the same: Controlled delivery formulations of creatine and a method of using the same are disclosed. Creatine is combined with an encapsulation/delivery agent and/or excipient, which act in such a way as to provide controlled delivery of creatine. This delivery profile substantially increases the period of time over which levels of creatine... Agent: Welsh & Katz, Ltd

20070065510 - Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum: The present invention provides a controlled release device for sustained or pulsatile delivery of pharmaceutically active substances for a predetermined period of time. This invention further provides such device in which sustained or pulsatile delivery is obtained by the unique blend and intimate mixture of pharmaceutically active substance with a... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070065512 - Modified and immediate release formulations of memantine: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or... Agent: Darby & Darby P.C.

20070065513 - Stable lansoprazole formulation: A stable composition comprising a substrate comprising lansoprazole (preferably in the base form), without any alkaline agent; a subcoating layer containing alkaline agent; and an enteric coating layer. The substrate is preferably an inert core with an active layer (containing lansoprazole) layered over it.... Agent: Martin D Moynihan Prtsi Inc

20070065516 - Composition improved in the solubility or oral absorbability: An object of the present invention is to provide a composition improved in the solubility or oral absorbability. The present invention provides a composition which comprises three components of a slightly water-soluble component, a surfactant and a hydrophilic polymer, and is obtainable by wet granulation in the presence of water.... Agent: Eckert Seamans Cherin & Mellott

20070065514 - Method for enhancing immune responses in mammals: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to... Agent: Needle & Rosenberg, P.C.

20070065515 - Methods and compositions for treating skin lines and wrinkles and improving skin quality: Methods and compositions for improving skin quality are disclosed. The methods include applying a solution of about 20-30% pre-wetting agent, such as hyaluronic acid, to a skin surface with concurrent dermabrasion treatment. These methods lead to significant improvement in the treatment of skin aging. Compositions for improving skin quality are... Agent: Klarquist Sparkman, LLP

20070065517 - Modafinil pharmaceutical compositions: Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.... Agent: Woodcock Washburn LLP

20070065518 - Colostrum compositions and methods: Colostrum products and a methods of using the colostrum products are provided. Methods are provided for preparing the colostrum products, which may be filtered and sterilized. The colostrum products may be injected, illustratively subcutaneously and intravenously, to provide an animal protection from disease.... Agent: Ice Miller LLP

20070065519 - Copper ion-producing composition: It is an object of the present invention to provide a copper ion-producing composition that has a copper ion (mineral)-based germicidal activity against Legionella spp., Escherichia coli, Staphylococcus aureus, and saprophytic bacteria occurring in the water in drinking water storage tanks, hot springs, bathhouses, and pools, and that can supply... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070065520 - Mri contrast medium composition for oral administration: The use of a physiologically acceptable manganese (II) compound and an uptake promoter in the form of one or more amino acids for the manufacture of an MRI contrast composition for oral administration and MRI examination of the liver in a ratio of Mn to promoter higher than that at... Agent: Buchanan, Ingersoll & Rooney PC

20070065521 - Composition and method for treating iron deficiency anemia: A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same.... Agent: Myers & Kaplan, Intellectual Property Law, L.L.C.

20070065522 - Administration of high potency platinum compound formulations by inhalation: Provided is a method for treating a patient having cancer. The method includes administering high potency lipid-platinum compound formulations to the patient's respiratory tract. Also provided is a method of reducing treatment times for administering platinum compound formulations to a patient in need thereof by administering high potency lipid-platinum compound... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070065523 - Method and composition for reducing body weight and improving control of body lipids: Methods and composition using plants from the Irvingiaceae family to reduce or prevent one or more symptoms of Syndrome X in a mammal and provide numerous other health related benefits. Methods and compositions using the Irvinga gabonensis plant to reduce lipid levels, BMI and body weight, blood pressure, triglyceride levels,... Agent: Rehrig Pacific

20070065524 - Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar: The present invention relates to the pharmaceutical composition comprising mainly the guaiacol family compound and the syringol family compounds, extracted from natural plant vinegar. The present invention provides that pharmaceutical compositions has effects of treating oxidative toxicity, regulating blood glucose level, improving blood flow, treating hangover and treating atopic dermatitis... Agent: Welsh & Katz, Ltd

20070065525 - Extract of ogalpi, erectile dysfunction fanning healthy food and erectile dysfunction treating agent containing the same: The present invention relates to an alcohol extract of ogalpi, erectile dysfunction improving health food and a treating agent containing the same, more precisely, an alcohol extract of ogalpi having an effect of improving erectile dysfunction, erectile dysfunction improving health food and an erectile dysfunction treating agent containing the same.... Agent: Lucas & Mercanti, LLP

20070065526 - Methods and compositions comprising panax species: The present invention comprises compositions comprising essential oils, ginsenosides, and polysaccharides. The present invention comprises methods comprising sequential solvent extraction and polymer absorbent purification to obtain fractions comprising essential oils, ginsenosides, and polysaccharides. The compositions of the present invention may be used in forms such as tablets, gel caps, or... Agent: Robert T. Gow

20070065527 - Activated citrus peel extract: The present invention relates to composition comprising an activated citrus peel extract (ACPE) prepared by an activation method which includes exposure of citrus peels to at least one plant or animal pathogen. The ACPE comprises at least one of the following: oligosaccharides, short peptides, flavonoid glycosides, fatty acids, and triglycerides.... Agent: Nath & Associates

20070059239 - Process for the preparation of radioactive labeled estradiol: A method for producing a high yield of an estradiol labeled at the 16-alpha position thereof with a radioactive iodine, especially 123I, for use as an imaging agent. The method includes the step of mixing a source of 123I sodium iodine with 16-beta-bromoestradiol-17-beta and benzo-15-crown-5-ether in a water and organic... Agent: Law Office Of John C. Mcmahon

20070059240 - Method for diagnosis of chronic allograft rejection: The present invention provides a method for the diagnosis of chronic rejection in allografts. The method comprises identification of tertiary lymphoid organs (TLO) in the transplanted organs as a marker of chronic rejection by immunohistochemical detection for the presence of specific TLO antigens in biopsy samples or by radiographic imaging... Agent: Hodgson Russ LLP

20070059241 - Neutralizing human anti-igfr antibody: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070059242 - Methods to identify therapeutic agents: As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cholesterol oxidation or ozonation products that can act as chemotactic attractants of macrophages, can promote differentiation of monocytes into macrophages and can increase expression of E-selectin and Class A scavenger receptor (SR-A). The present... Agent: The Scripps Research Institute

20070059243 - Method of treating or inhibiting the development of brain inflammation and sepsis: A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070059245 - Protein cages for the delivery of medical imaging and therapeutic agents: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.... Agent: Robin M. Silva Dorsey & Whitney LLP

20070059246 - Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability: The use of contrast agents of molecular weight lower than 5000 Dalton and including at least one residue of a biliary acid for the preparation of diagnostic contrast compositions for the microvascular permeability assessment is disclosed.... Agent: Nixon & Vanderhye, PC

20070059247 - Deposit contrast agents and related methods thereof: A method for generating an enhanced ultrasound image comprises intravenously administering to a subject a plurality of microbubbles of sufficient diameter to lodge in the microvasculature of a subject. An ultrasound image of a portion of the subject is generated wherein the image is enhanced by one or more of... Agent: University Of Virginia Patent Foundation

20070059248 - Oxygen delivery agents and uses for the same: The present invention describes, inter alia, oxygen delivery agents or blood substitutes comprising a fluorinated gas and a stabilizing material, uses for the oxygen delivery agents or blood substitutes, and apparatus for making and delivering the oxygen delivery agents or blood substitutes.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Rudnick Gray Cary US LLP

20070059244 - Optical imaging of rheumatoid arthritis: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.... Agent: Millen, White, Zelano & Branigan, P.C.

20070059249 - Acute treatment of social phobia: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts... Agent: Heller Ehrman LLP

20070059251 - Method of attenuating bruise formation: The present invention provides a method of attenuating the formation or reducing the severity of a bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and... Agent: Leydig Voit & Mayer, Ltd

20070059250 - Sprayable personal lubricant: This invention relates to personal lubricant compositions that are capable of being sprayed to a targeted area while maintaining lubricity.... Agent: Philip S. Johnson Johnson & Johnson

20070059252 - Freeze-dried fsh/lh formulations: The invention relates to the field of pharmaceutical formulations of a mixture of follicle stimulating hormone (FSH) and luteinising hormone (LH), and to methods of producing such formulations.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070059253 - Foamable pharmaceutical compositions and methods for treating a disorder: Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may... Agent: Gary M. Nath Nath & Associates PLLC

20070059254 - Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof: The present invention provides novel compositions for the delivery of a 5-hydroxytryptamine (5-HT) agonist across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 9.9, thereby facilitating the substantially complete conversion of the... Agent: Townsend And Townsend And Crew, LLP

20070059255 - Methods and compositions for treating disease or injury: The present invention is drawn to methods of treating disease or injury. In particular, the invention provides methods for treating viral infections, bacterial infections, fungal infections, and cancerous tissue. The methods include the administration of an aqueous composition that can comprise an aqueous vehicle, including water, from 0.0001 wt %... Agent: Thorpe North & Western, LLP.

20070059256 - Dentifrice composition: Provided is a dentifrice composition containing erythritol, which is excellent in storage stability and the persistence of a cool feeling and gives a higher refreshing feeling. The dentifrice composition comprises: (A) 15 to 50 weight % of erythritol having a particle size of less than 355 μm; (B) 10 to... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070059257 - Dentinal composition for hypersensitive teeth: A composition for the treatment of sensitive teeth comprising a suitable carrier and a desensitizing amount of: a) at least one tubule blocking agent preferably a combination of two such agents; and b) a nerve desensitizing agent selected from the group consisting of at least one potassium salt at least... Agent: Glaxosmithkline Corporate Intellectual Property - Uw 2220

20070059260 - Benzyl-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening: are useful active agents for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or preventing and/or limiting the depigmentation and/or bleaching thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for preventing and/or limiting the canities of human keratin... Agent: Buchanan, Ingersoll & Rooney PC

20070059259 - Compositions and methods for mitigating skin irritation: The invention relates to a composition and a method for mitigating redness or inflammation of mammalian skin comprising administering to mammalian skin a composition consisting of an effective amount of alkanolamine, feverfew or soy or mixtures thereof, one or more optional benefit agents and one or more cosmetically acceptable carriers.... Agent: Philip S. Johnson Johnson & Johnson

20070059258 - Photostable organic sunscreen composition: The present invention relates to a sunscreen capsule comprising i) at least one UV-A organic sunscreen and ii) at least one photostabilizer; furthermore it relates to a composition for topical application comprising these capsule and methods of production and use of these capsules and compositions.... Agent: Millen, White, Zelano & Branigan, P.C.

20070059261 - Antimycotic nail polish formulations comprising substituted 2-aminothiazoles as an active substance: Antimycotic nail polish formulations for the treatment of various fungal infestations are disclosed in this application. The formulations comprise substituted 2-aminothiazole compounds disclosed herein.... Agent: Jones Day

20070059262 - Solid skin care composition comprising multiple layers: The present invention relates to a solid skin care composition comprising: (a) a first layer which is solid at 45° C. and which is selected from the group consisting of a water-in-oil emulsion, an oil-in-water emulsion and an oil dispersion; and (b) a second layer which is a pressed powder... Agent: The Procter & Gamble Company Intellectual Property Division

20070059263 - Solid skin care composition comprising multiple layers: The present application relates to a solid skin care composition comprising: (a) a first layer which is solid at 45° C. and which is a water-in-oil emulsion or an oil-in-water emulsion; and (b) a second layer which is solid at 45° C. and which is an oil dispersion comprising a... Agent: The Procter & Gamble Company Intellectual Property Division

20070059264 - Reduction of hair growth: A composition for reducing hair growth includes α-difluoromethylomithine, an antiperspirant salt or deodorant active ingredient, and a vehicle.... Agent: Fish & Richardson P.C.

20070059265 - Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers: are useful active agents for inducing and/or stimulating the growth of mammalian keratin fibers and/or reducing the loss and/or increasing the density thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for caring for or making up the hair or the... Agent: Buchanan, Ingersoll & Rooney PC

20070059266 - Sprayable personal lubricant: This invention relates to personal lubricant compositions that are capable of being sprayed to a targeted area while maintaining lubricity.... Agent: Philip S. Johnson Johnson & Johnson

20070059267 - Associative water-soluble cellulose ethers: The present invention relates to a water-soluble associative cellulose ether having a DP viscosity from 250 to 20,000 mPa·s, measured at a concentration of 1% by weight, and a molecular substitution, MS, from 0.0001 to 0.005 of a hydrophobic substituent containing an unsubstituted or substituted hydrocarbon group of 8-24 carbon... Agent: Akzo Nobel Inc.

20070059268 - Compositions, methods and kits for treating allergic dermatitis of skin: The invention includes compositions suitable for removal of urushiol from skin having been exposed thereto, which compositions contain an ethoxylate and sodium lauroyl sarcosinate, methods for treating allergic dermatitis of skin having been exposed to urushiol, and kits suitable for treatment of allergic dermatitis,... Agent: Philip S. Johnson Johnson & Johnson

20070059269 - Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer: A regime or regimen for promoting cohesion and/or organization of the epidermal horny layer, notably for promoting homogeneity and/or clarity of the complexion, for improving the homogeneity and/or the staying power of makeup compositions on the skin or the lips, for preventing impairment of the horny layer induced by a... Agent: Buchanan, Ingersoll & Rooney PC

20070059273 - Novel biodegradable biofouling control coating and method of formulation: An antifouling coating including a polymer made by crosslinking a chitosan with a blocked polyisocyanate.... Agent: Naval Research Laboratory Associate Counsel (patents)

20070059270 - Ion exchange resin treated to control swelling: The present invention provides a method and composition are provided that includes an ion exchange resin treated with from between about 0.01 to about 10 percent by weight of one or more sugar alcohols in contact with one or more ionic pharmaceutically active drug.... Agent: Chalker Flores, LLP

20070059274 - Ophthalmic compositions containing a pva/borate gelling system: Ophthalmic compositions containing a polyvinyl alcohol/borate gelling system are described. The system forms a gel or partial gel when the composition is applied to the eye. The compositions are particularly useful as ocular lubricants or artificial tears.... Agent: Alcon

20070059275 - Antibody toxin conjugates: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070059276 - Bi-modal hyaluronate: Formulations and methods for protecting cell layers and tissues exposed to trauma are disclosed. Different molecular mass fractions of the same polymer can be used to better control the physical and chemical properties of the formulation. In this manner the benefits of both fractions, and not just the benefits of... Agent: Advanced Medical Optics, Inc.

20070059277 - Sachet formulation for amine polymers: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation... Agent: Genzyme Corporation Legal Department

20070059272 - Modulation of microbial pathogen-host cell interactions: The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial... Agent: Marshall, Gerstein & Borun LLP

20070059271 - Polyethylene glycol/polycation block copolymers: The invention provides block copolymers formed of poly(ethylene glycol) segments and poly(amino acid derivative) segments having side chains of at least one kind of specific amine residue. The invention also provides polyion complexes of such copolymers with polynucleotides and the like. These block copolymers are useful as carriers for in... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070059278 - Anhydrous composition containing an acid-acid buffer system: This invention relates to anhydrous compositions and methods of maintaining healthy vaginal pH to control vaginal odor. Such compositions may be applied to the vaginal area to lower vaginal pH and assist in maintaining such pH over a period of time.... Agent: Philip S. Johnson Johnson & Johnson

20070059281 - Composite bone graft substitute cement and articles produced therefrom: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is... Agent: Alston & Bird LLP

20070059282 - Immunocytokine sequences and uses thereof: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment... Agent: Kirkpatrick & Lockhart Nicholson Graham LLP

20070059280 - Inhibitors of colony stimulating factors: A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of... Agent: Warner-lambert Company

20070059279 - Pharmaceutical composition for preventing or treating malignant glioma: An object of the present invention is to provide a novel malignant glioma antitumor agent and malignant glioma antitumor agent for animals, and in order to achieve this object, in the present invention a polypeptide indicated by the following (a) or (b), or a mixture thereof, is contained in a... Agent: Lahive & Cockfield, LLP

20070059283 - Feline il-18 nucleic acid molecules: The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules... Agent: Heska Corporation Intellectual Property Dept.

20070059284 - Methods of treating infections using il-21: Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be... Agent: Zymogenetics, Inc. Intellectual Property Department

20070059285 - Human serum albumin-free stabilized interferon liquid formulations: A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, a surfactant, an isotonicity agent and an antioxidant. Preferably the interferon is human recombinant IFN-beta.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070059286 - Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity: The present invention describes DNA vaccines that encode for and direct the coincident expression of an antigen and an ADP-ribosyltransferase toxin that is devoid of ADPribosyltransferase activity and methods for vaccinating animals with the same. The DNA vaccines are useful for vaccinating against viral, bacterial and parasitic pathogens.... Agent: Intellectual Property / Technology Law

20070059291 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv): The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.... Agent: Viksnins Harris & Padys Pllp

20070059289 - Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20: Methods of improving cardiac function and/or methods for attenuating and/or prevention cardiac remodeling in an individual's heart comprising administering to an individual an effective amount of Heat-Shock Protein Hsp20 or an agent that increase the levels of and/or the activity of Hsp20 are provided.... Agent: Dinsmore & Shohl, LLP

20070059287 - Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same: The present invention relates to a transcriptional regulatory sequence with enhanced tumor-specificity and strength and a recombinant vector comprising the transcriptional regulatory sequence. More particularly, the present invention relates to a transcriptional regulatory sequence comprising a human telomere reverse transcriptase (hTERT) promoter linked to a nucleotide sequence that comprises one... Agent: Sheridan Ross PC

20070059290 - Transcriptional regulation of target genes: The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript... Agent: Klauber & Jackson

20070059288 - Treatment for heart disease: The present invention provides a system for treating heart disease using a combination of pro-angiogenesis therapy and cellular cardiomyoplasty. The system is particularly useful in treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. A pro-angiogenic factor (e.g., VEGF) or a means of... Agent: Choate, Hall & Stewart LLP

20070059294 - Therapeutiv preparation for hematopoietic disease: The present invention provides therapeutic formulations for hematopoietic diseases comprising as effective ingredient, synoviolin which is reported to be isolated as a synovial cell protein and its gene, and therapeutic methods and such comprising the step of administering the protein or polynucleotide. The present invention also provides as models of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070059292 - Use of enterococcus faecium strains for curing hepatic insufficiency and for regenerating and intensifying metabolism in a liver: The invention relates to the use of enterococcus faecium (VKPM B-3490) and enterococcus faecium M-3185 (VKPM B-349 i) strains, a composition and a Bilaktin preparation based on said stains for curing a hepatic insufficiency which is exhibited by hepatodepressive, cytolytic and cholestatic syndromes and by intrahepatic portal hypertension during hepatic... Agent: Ladas & Parry

20070059295 - Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces: Organisms, compositions, and methods for at least partially reducing the formation of a biofilm and/or at least partially removing a biofilm are provided. The organisms, compositions, and methods may be used on biotic and abiotic surfaces.... Agent: Calfee Halter & Griswold, LLP

20070059298 - Method for administering a vaginal care composition: A vaginal care composition is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner. The composition comprises viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures,... Agent: William Collard Collard & Roe, P.C.

20070059297 - Methods and compositions for improving visual acuity: Compositions and methods for enhancing visual acuity in animals are disclosed. The compositions and methods utilize long chain polyunsaturated fatty acids.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070059296 - Probiotic composition having acid-resistant enteric coating: A probiotic composition essentially comprises 15 to 20 wt % of milk powder, 25 to 30 wt % of corn starch, 8 to 15 wt % of modified starch (capsul), 10 to 15 wt % of ethylcellulose, 5 to 15 wt % of bacterial broth, and 10 to 15 wt... Agent: J.c. Patents

20070059293 - Tissue engineered construct for supplementing or replacing a damaged organ: The present invention provides methods and compositions for supplementing or replacing a damaged organ. The damaged organ to be supplemented or replaced in accordance with the present invention include, for example, kidney, heart, liver, spleen, pancreas, bladder, ureter and urethra. In one embodiment, the tissue-engineered construct of the invention has... Agent: David S. Resnick

20070059299 - S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection: The present invention relates to pharmaceutical compositions for the treatment of herpes simplex virus infections, including HSV-1 and HSV-2 infections, including an inhibitor of S-adenosyl methionine decarboxylase in combination with another agent for treating such infections, such as acyclovir, in an acceptable carrier.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070059300 - Compounds and compositions to control abnormal cell growth: Methods and regimens for stimulating proliferation and inhibiting death of skin cells in wounded, non-wounded healthy and unhealthy, or transplanted skin and skin cell suspensions are provided. The methods and regimens include a step of administering to an area of host skin and/or transplanted skin a combination of lactoferrin and... Agent: Faegre & Benson LLP Patent Docketing

20070059302 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20070059303 - Compositions and methods for the diagnosis and treatment of immune disorders: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is... Agent: Millennium Pharmaceuticals, Inc.

20070059301 - Modified antibody fragments: The present invention provides an antibody Fab or Fab′ fragment to which at least one effector molecule is attached characterized in that the heavy chain in the fragment is not covalently bonded to the light chain and both the interchain cysteine of CL and the interchain cysteine of CH1 have... Agent: Woodcock Washburn LLP

20070059304 - Anti-trkb monoclonal antibodies and uses thereof: The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal... Agent: Choate, Hall & Stewart LLP

20070059305 - Neutralizing human anti-igfr antibody: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070059306 - B-cell reduction using cd37-specific and cd20-specific binding molecules: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further... Agent: Marshall, Gerstein & Borun LLP

20070059307 - Biological products: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the... Agent: Cozen O'connor, P.C.

20070059308 - Human monoclonal antibodies against membrane proteins: Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat... Agent: Wilson Sonsini Goodrich & Rosati

20070059309 - Anti-interferon-alpha antibodies: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders... Agent: Merchant & Gould PC

20070059312 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20070059313 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070059311 - Regulation of the hedgehog signaling pathway and uses thereof: The present invention provides molecular mechanism leading to the development of cancers associated with hedgehog signaling pathway. These cancers may develop as a result of a chronic bacterial or a chronic viral infection. The present invention provides methods for early detection of such cancers. Additionally, it also provides measures that... Agent: Benjamin Aaron Adler Adler & Associates

20070059310 - Therapeutic combination compositions and methods of using same: The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070059314 - Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer: The present invention relates to the use of a protein characterized in that it comprises or is constituted by the NOV protein, represented by the sequence SEQ ID NO: 2, or a fragment of this protein, providing that this fragment exhibits an angiogenesis-inhibiting activity, or any sequence derived from the... Agent: Nixon & Vanderhye, PC

20070059315 - Prostate stem cell antigen vaccines and uses thereof: This invention relates to the identification of prostate stem cell antigen (PSCA) as a target of clinically relevant antitumor immune responses. The invention provides vaccines comprising PSCA, or fragments thereof, which are useful in inducing antitumor immune responses, including PSCA specific CD8+ T cell responses. Methods of using the compositions... Agent: Morrison & Foerster LLP

20070059316 - Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents: Provided herein are conjugates, kits, articles of manufacture and methods for detection, diagnosis and treatment by photodynamic therapy of certain undesired biological substrate targets, including, but not limited to bacteria, viruses, and other pathogenic microorganisms, tumors and hyperproliferative tissue. In particular, the conjugates provided include a fluorophore or photosensitizer linked... Agent: Seed Intellectual Property Law Group PLLC

20070059318 - Lipid nano particulates containing antigens as cancer vaccines: The present invention provides compositions and method for increasing the immunogenicity of antigens such as tumor antigens. The compositions comprise liposomes such that they are suitable for targeting denderitic cells. The compositions preferably comprise at least 50% liposomes which are less than 120 nm. The liposomes comprise a cationic lipid... Agent: Hodgson Russ LLP

20070059317 - Potent immunostimulants from microalgae: Immunostimulatory polysaccharides can be preferentially extracted from food-grade microalgae using an aqueous ethanol extraction procedure. The resulting preparations exhibit extremely potent immunostimulatory activity. The preferential extraction of these immunostimulatory polysaccharides is dependent on the concentration of ethanol used and the extraction temperature. The most efficient conditions are 50% ethanol concentration... Agent: Hunton & Williams/new York Intellectual Property Dept.

20070059319 - Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants: A method of screening for agents that stimulate the innate immune system in mammals employs markers that respond to Toll-like receptor binding. Agents identified in the assay boost both innate and adaptive immune responses, when administered alone or in combination with vaccines.... Agent: Foley And Lardner LLP Suite 500

20070059320 - Method for ameliorating pain by modification of nmda receptors through inhibition of src: The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex.... Agent: Mchale & Slavin, P.A.

20070059321 - Methods of reducing minimal inhibitory concentration of antibiotics and compositions resulting therefrom: It is desirable to use lower doses of antibiotics in treating bacterial infections, as antibiotics are expensive and may come with undesirable side effects including kidney and/or liver damage. Moreover, using a high dose of antibiotics may lead to development of resistance in bacteria to the antibiotics themselves. More importantly,... Agent: Buchanan, Ingersoll & Rooney PC

20070059323 - Dna composition encoding an immunogenic vegf receptor peptide and methods of use thereof: A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1),... Agent: Olson & Hierl, Ltd.

20070059322 - Site specific listeria integration vectors and methods for using the same: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple... Agent: Bozicevic, Field & Francis LLP

20070059324 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham Mccutchen. LLP

20070059325 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070059326 - Escherichia coli-derived vaccine and therapy against botulism: A method of producing botulinum toxin C-terminal receptor binding domain (HCR) is disclosed. The one embodiment, the method comprises the steps of (a) preparing E. coli transformed with an expression vector comprising DNA encoding HCR protein, (b) inducing expression of the HCR protein at a reduced temperature in a culture... Agent: Quarles & Brady LLP

20070059327 - Streptococcus equi compositions and methods of use: This invention relates to compositions comprising live, attenuated Streptococcus equi (S. equi), or a fractional extract of S. equi, in combination with at least one immunostimulant for stimulating mucosal immunity, such as saponin. The invention also relates to methods of preparation and dosage forms containing the composition of the invention... Agent: Darby & Darby P.C.

20070059328 - Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma (obstructive lung disease): The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).... Agent: Morrison & Foerster LLP

20070059329 - Unexpected surface proteins in meningococcus: 217 proteins have, contrary to expectations, been found in the membrane of Neisseria meningitidis. Of these 217, 76 in particular evaded all algorithmic methods for predicting membrane localisation. Existing knowledge of protein trafficking pathways in meningococcus does not explain how or why these proteins are located in the bacterial membrane... Agent: Novartis Vaccines And Diagnostics Inc.

20070059330 - Insecticidal agent, method for the preparation thereof and a method for controlling insects: The present invention provides an insecticidal agent useful for the controlling the insect pests belonging to the order Lepidoptera viz. Helicoverpa armigera, Pectinophora gossypiella, Spodoptera litura, or Earias vitella or mixed populations thereof on different crops comprising inorganic molecular sieve dissolved in water and naturally occurring inert adhesive such as... Agent: Schweitzer Cornman Gross & Bondell LLP

20070059332 - Multi purpose contact lens care compositions including propylene glycol or glycerin: Multi-purpose solutions for contact lens care provide substantial lens wearer/user comfort and/or acceptability. Such solutions include an aqueous liquid medium; an antimicrobial component, preferably a biguanide polymer present in an amount of less than about 5 ppm; propylene glycol or glycerin in an amount sufficient to increase antimicrobial activity; a... Agent: Advanced Medical Optics, Inc.

20070059331 - Synergistic mixtures of c6- to c12-alkanediols and tropolone (derivatives): l

20070059333 - Pesticide strips for control of mites in honeybees: Pesticide strips used to control parasitic mites in honeybees. The pesticide strips are designed to have a lifetime or period of existence, after which the strip no longer exists in its original form. The strip breaks down, such as by disintegration, dissolving, decomposition, being eaten or carrier away, or otherwise... Agent: Merchant & Gould PC

20070059335 - Seeding implantable medical devices with cells: Apparatus and methods for seeding an implantable medical device, such as a vascular prosthesis, with cells, such as endothelial cells, are described. The invention supports techniques for seeding a luminal surface of the device with axial centrifugation. Cells are introduced in suspension into the lumen of the device. The introduction... Agent: Shumaker & Sieffert, P. A.

20070059334 - Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles: The present invention generally provides implantable articles and methods of forming implantable articles from a crosslinked ultrahigh molecular weight polyethylene (“UHMWPE”) blend stabilized with Vitamin E. The crosslinked UHMWPE blend may be prepared by combining the UHMWPE material and vitamin E prior to irradiating the UHMWPE blend with electron beam... Agent: Wood, Herron & Evans, LLP (zimmer)

20070059336 - Anti-angiogenic sustained release intraocular implants and related methods: Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three... Agent: Allergan, Inc.

20070059338 - Compositions and techniques for localized therapy: A therapeutic medical article is provided which comprises a medical article, a precursor compound and an activator compound. The medical article is adapted, upon administration to a patient, to release the precursor compound and the activator compound such that the activator compound interacts with the precursor compound and converts the... Agent: Mayer & Williams PC

20070059337 - Cyclic acetal biomaterials: A novel class of Cylic Acetal biomaterials (CABs) based on a cyclic acetal unit is disclosed and claimed by Applicants. Two novel biomaterials suitable for use in a variety of biological applications including in the orthopedic field for joint and cartilage replacement and/or repair, and bone cement. The biomaterials are... Agent: Jacobson Holman PLLC

20070059339 - 1-o-beta-d-glucopyranosylgeraniol-10,5-olide and use thereof: A novel natural compound having various therapeutically effects is provided. The compound is obtainable from Sibiraea leaves by aqueous extraction and is represented by a formula (1) as follows.... Agent: Nixon & Vanderhye, PC

20070059340 - Omega-3 fatty acids encapsulated in zein coatings and food products incorporating the same: Disclosed are processes for stabilizing omega-3 fatty acids for use in food products. The processes permit creation of a variety of food forms and food ingredients that contain omega-3 fatty acids like docosahexaenoic acid and eicosapentaenoic acid wherein these foods and food forms are stable for months without developing fishy... Agent: Randall L. Shoemaker Dickinson Wright PLLC

20070059341 - Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy: The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R−1 (I)) is used as a food additive, a food product, physiologically-active substances and active ingredients of forage additives and of forage, in cosmetic... Agent: Ladas & Parry LLP

20070059342 - Method and palatable pharmaceutical composition for treating herpes in animals: An animal medication for orally treating herpes is formed of L-Lysine monohydrochloride, fishmeal and stevia sweetener.... Agent: Jacobson Holman PLLC

20070059343 - Pet life: My idea/invention of “PetLife” is the formulation of unique chemical formulas for the production of fortified instant liquid energy drink for dogs and cats, in the individual and dual sense; as to say “Pet Life Dogs”, “Pet Life Cats” and “Pet Life General”. To boost there vitality and strength within... Agent: Sridat Chinsammy

20070059344 - Use of a high-oleic and high-tocol diet in combination with a non-tocol antioxidant for improving animal meat quality: A novel method for improving the meat quality of an animal is provided. In one embodiment, the method comprises feeding the animal a diet supplemented with oleic acid and tocols and subsequently formulating the meat with a non-tocol antioxidant such as rosemary extract. The source of the oleic acid and/or... Agent: Pioneer Hi-bred International, Inc.

20070059347 - Antibacterial fiber assembly and production method and uses thereof: To provide a fiber assembly in which the durability of antibacterial property, especially the durability of antibacterial property against moisture is improved and there is provided a fiber assembly principally comprising polyolefin, wherein said fiber contains an antibacterial agent and a suspending agent, and has a branched structure.... Agent: Amin, Turocy & Calvin, LLP

20070059346 - Film comprising therapeutic agents: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070059345 - Method for tissue growth: A method for promoting or stimulating growth of tissue (22) comprising providing an element (23) which is adapted to receive blood, locating the element (23) in contact with the tissue (23) with at least one portion of the element (23) extending away from an external surface of the tissue (22),... Agent: Olson & Hierl, Ltd.

20070059348 - Wound care device: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of... Agent: Jacobson Holman PLLC

20070059350 - Agents for controlling biological fluids and methods of use thereof: Therapeutic formulations adapted for positive-pressure application for controlling biological fluid at a desired site in a subject, absorbent articles comprising therapeutic formulations, and anti-infective devices coated with therapeutic formulations, said formulations comprising about 25% to about 99% by weight liquid-crystal forming compound and 0% to about 75% by weight solvent.... Agent: Bromberg & Sunstein LLP

20070059349 - Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate: The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive,... Agent: Foley And Lardner LLP Suite 500

20070059351 - Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods: The present invention is drawn to a transdermal patch for the delivery of a nitric oxide-donor and a second active agent. The patch can comprise a backing layer and an active agent-containing composition which is supported at least in part by the backing layer. The active agent-containing composition can include... Agent: Thorpe North & Western, LLP.

20070059353 - Polyarginine-modified liposome having nuclear entry ability: With the object of providing a liposome having cellular and nuclear entry ability, to achieve this object, a liposome is provided having on its surface a peptide comprising multiple consecutive arginine residues, and specifically a liposome is provided wherein the peptide is modified with a hydrophobic group or hydrophobic compound... Agent: Lahive & Cockfield, LLP

20070059352 - Therapeutic liposomes: The invention provides methods for correcting an imbalance of one or more entities in a mammal, as well as therapeutic liposomes and compositions for use with such methods.... Agent: Viksnins Harris & Padys Pllp

20070059355 - Liquid filled delivery system: The present invention provides a delivery system comprising: (a) a container which is a formed body obtained from a film forming composition comprising at least one polysaccharide or polysaccharide derivative; (b) a liquid fill comprising a matrix composition of at least one solvent which is both polar and hygroscopic or... Agent: Rosemary M. Miano Attorney For Applicant

20070059354 - Sustained release dosage forms of oxcarbazepine: This invention relates to a once a day sustained release dosage form suitable for oral administration of oxcarbazepine. The once a day sustained release dosage form of oxcarbazepine includes oxcarbazepine and hydroxypropyl methylcellulose (HPMC) having a viscosity of 11,000 to 25,000 cps.... Agent: Ranbaxy Inc.

20070059357 - Adiponectin production enhancer: The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070059361 - Fast-disintegrating epinephrine tablets for buccal or sublingual administration: Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen).... Agent: Wilson Sonsini Goodrich & Rosati

20070059359 - Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof: The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising non-micronized (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20070059358 - Matrix adjuvants and the drop pills prepared with them: The present invention relates to the matrix adjuvants for drop pills and the preparation of the drop pills. The matrix adjuvants for drop pills of the present invention comprise new matrix adjuvants with or without the plastifying components, which are typically natural matrix adjuvants derived from plants and of safety... Agent: Kaplan Gilman Gibson & Dernier L.L.P.

20070059356 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070059360 - Water-dispersible anti-retroviral pharmaceutical compositions: Provided herein are water-dispersible pharmaceutical compositions comprising a combination of one or more anti-retroviral drugs useful for the treatment of Human Immunodeficiency Virus (HIV) infections. Also provided are processes for preparing such water-dispersible pharmaceutical compositions.... Agent: Ranbaxy Inc.

20070059362 - Effervescent rehydrating beverage tablet/granules: Effervescent tablets, powders and granules are provided which may be dissolved in water to produce an effervescent rehydrating beverage. The effervescent tablet, powder and granule compositions of the invention deliver electrolytes and carbohydrates at levels that provide hypotonic, isotonic or slightly hypertonic solution when dissolved in water, with acceptable taste.... Agent: Merchant & Gould PC

20070059364 - Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity: The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070059363 - Method of preparing mixed formulation of sustained release microspheres by continuous one-step process: Disclosed is a method for preparing a mixed formulation of sustained release microspheres with various compositions by a continuous one-step process. The present method is characterized by preparing the mixed formulation of sustained release microspheres with different compositions by a continuous one-step process by continuously introducing the mixed fluids into... Agent: Tanya A Arenson Medlen & Carroll

20070059365 - Novel formulation of ropinirole: The present invention relates to novel formulations of ropinirole for oral administration and to their use in the treatment of diseases which can prevent or disturb sleep, particularly Restless Legs Syndrome (RLS).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070059366 - Sustained-release formulation and uses thereof: The present invention provides sustained-release formulations useful and methods for using the same.... Agent: Choate, Hall & Stewart LLP

20070059367 - Drug delivery system and associated methods: A modified release pharmaceutical composition is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the composition has a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters... Agent: Thorpe North & Western, LLP.

20070059368 - Modified release formulations of anti-irritability drugs: Modified or extended release formulations containing mesalamine compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved mesalamine formulations such as PENTASA®.... Agent: Thorpe North & Western, LLP.

20070059369 - Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders: The present invention relates to a subcutaneous delivery system comprising a biodegradable polymeric matrix and at least one of the pharmacologically active substances of general formula (I): wherein A represents an amino group —NH2 or an ammonium group —NH3+ or a residue of general formula (II): wherein each of X1... Agent: Nixon & Vanderhye, PC

20070059370 - Method and apparatus for fabricating nanoparticles: An apparatus and method for forming nanoparticles employs an inkjet dispenser and a nanoparticle formation device. The inkjet dispenser includes at least one orifice. A liquid solution with a substance to be transformed into nanoscale is received in the inkjet dispenser, and is dispensed from the at least one orifice... Agent: Quintero Law Office, PC

20070059374 - Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.... Agent: K&l Gates, LLP

20070059373 - Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and... Agent: K&l Gates, LLP

20070059371 - Nanoparticulate ebastine formulations: The invention is directed to compositions comprising at least one nanoparticulate H1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist particles, such as ebastine, have an effective average particle size of... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070059375 - Tissue treatment: A method of treating tissue includes placing substantially spherical polymer particles in the tissue. The particles include an interior region having relatively large pores and a first region substantially surrounding the interior having fewer relatively large pores than the interior region.... Agent: Fish & Richardson PC

20070059372 - Use of autologous sediment from fluid aspirates as vehicles for drug delivery: A method of using fluid aspirates as vehicles for drug delivery by collecting a fluid aspirate such as synovial joint effusion, pleural effusion, pericardial effusion, or ascites from a patient and centrifuging the fluid aspirate to provide a supernatant and a sedimented material. The sedimented material can optionally be further... Agent: Wilson Daniel Swayze, Jr.

20070059376 - Peptide conjugate: A platelet substitute which does not induce formation of unnecessary thrombi and intravascular coagulation of blood, by causing aggregation of resting platelets in the blood vessel, and has a specific aggregation action is provided. It was found as a result that a peptide conjugate, in which a synthesized form of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070059377 - Compositions and methods for the treatment of wounds and the reduction of scar formation: The present invention relates to methods and compositions for inhibiting scar formation on wound region. In certain embodiments, the methods include administering an alkalinization agent in combination with hyaluronic acid to a wound site to reduce the formation of scars at the wound site. Suitable alkalization agents include sodium bicarbonate,... Agent: Madeline I. Johnston, Esq. King & Spalding LLP

20070059378 - Medical composition for balancing bodily processes: Medical compositions and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed.... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070059379 - Inorganic resorbable bone substitute material: The invention relates in particular to a hydroxyl apatite/silica granular material of defined morphology, a highly porous bone substitute material based on this granular material and a glass ceramic material based in turn thereon as bone substitute material which is characterised by a variable mechanical strength, and shaped bodies of... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070059380 - Enhanced activity hydrogen peroxide disinfectant: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the solution; (ii) at least one anionic surfactant selected from the group consisting of... Agent: Clark & Brody

20070059381 - Treatment of amd with combination of ingredients: The present invention is directed to methods for enhancing current treatment regimens for age-related macular degeneration (AMD). The methods of the invention include intraocular delivery of AMD compositions along with antioxidant compositions. Alternatively, the methods of the invention include a daily regimen of ocular vitamin consumption in conjunction with other... Agent: Alcon Research Theresa J. Schultz, R&d Counsel (q-148)

20070059382 - Medical treatment of breast cancer with boric acid materials: Breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3 are treated by a method comprising: identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and providing a solution of boric acid or boric acid salts to the... Agent: Mark A. Litman & Associates, P.A.

20070059383 - Therapeutic composition and method of supporting the immune system: Disclosed is a therapeutic nutritional compound for treating and supporting the immune response in a mammal, particularly a human baby or child, and the treatment method. Additionally, the therapeutic nutritional compound can be used in conjunction with a vaccine or immunization regimen to reduce the potential undesirable effects caused by... Agent: Rogers Towers, P.A.

20070059384 - Medicament, in particular for the treatment of diabetes mellitus type 2: The present invention relates to a medicament, comprising plant material of Mascagnia eggersiana, subspecies, ecotypes or a combination thereof, or, respectively, comprising active compounds obtainable therefrom. The medicament is in particular suitable for the prophylaxis or treatment of diabetes mellitus type 2, and for improving the blood flow, in particular... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070059386 - Modular system for novel chinese herbal formulas: A modular system for novel Chinese herb formulas that allows for a practitioner skilled the basic principles of Traditional Chinese Medicine to employ a limited number of herbal formulations in various combinations to create safe custom treatments for individual patients for a wide variety of medical conditions.... Agent: Tsun-nin Lee

20070059385 - Safe pharmaceutical composition for treating and preventing cancer and method of use: The present invention provides a new method for extracting Homoharringtonine (HHT) by culture cells or culture plant tissues. Also, disclosed are methods of obtaining HHT from semi-synthesis and biosynthesis. The present invention disclosed that HHT combined with some botanical drugs could induce cancer cells to resemble normal cells. To add... Agent: Yaguang Liu

20070059387 - Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin: The present invention refers to a method for treating cancerous or pre-cancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.... Agent: Clark & Elbing LLP

20070059388 - Pharmaceutical composition containing a safe extracts of plants for the treating and preventing of diabetes and cardiovascular disease: This invention relates in general to the treatment of diabetes and cardiovascular disease. The pharmaceutical composition is composed of two ingredients: pumpkin polysaccharide and corn saponins and method of making the same.... Agent: Yaguang Liu

20070059389 - Preventives or remedies for infection, anti-endotoxin agents, vaccine adjuvants and growth promoters: A preventive or remedy for infection, an anti-endotoxin agents, a vaccine adjuvants and a growth promoter each comprising a sugar cane-derived extract as an active ingredient which agent is safe to man and animals. Also presented are foods and feeds comprising these agents.... Agent: Knoble, Yoshida & Dunleavy

20070059390 - Compositions for inhibiting or reducing inflammation of skin: The invention features a composition and methods for treating inflammation of skin, where the composition contains hydrocortisone and an avenanthramide.... Agent: Philip S. Johnson Johnson & Johnson

20070059391 - Antioxidant skin balm: This invention pertains to therapeutic antioxidant-lesion/abrasion/mole healing and/or removal compositions comprising therapeutically effective amount of antioxidant/free-radical fighting agents. In one embodiment, the lesion healing composition comprises (a) honey; (b) grape seed extract/proanthocyanidins powder; (c) ascorbic acid (vitamin C with rosehips); (d) d-alpha tocopheryl acetate (natural vitamin E); (e) soy oil;... Agent: Judith S. Perrin

20070059392 - Cox inhibitor: Methods and compositions for inhibition of both COX-1 and COX-2 are provided by this disclosure. The methods and compositions on the invention are effective for providing relief from pain.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070059393 - Composition for inhibition or prevention of bone density: The present invention relates to a composition for the inhibition or prevention of a bone mineral density reduction, or food and drink for use in such application, comprising isoxanthohumol or an isomerized hop extract as an active ingredient. According to the present invention, a bone mineral density reduction can be... Agent: Foley And Lardner LLP Suite 500

20070053832 - Drug product and process for making: The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from... Agent: Hollis-eden Pharmaceuticals, Inc.

20070053833 - High dose radionuclide complexes for bone marrow suppression: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20070053831 - Methods for binding agents to b-amyloid plaques: A method for labeling structures, such as β-amyloid plaques and neurofibrillary tangles, in vivo or in vitro, is provided and comprises contacting brain tissue with one or more compounds, preferably radiolabeled for detection by positron emission tomography (PET).... Agent: Christie, Parker & Hale, LLP

20070053830 - Particulate materials and compositions for radio therapy: Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of... Agent: Hunton & Williams LLP Intellectual Property Department

20070053834 - Radioligands for the trp-m8 receptor and methods therewith: One embodiment of the invention is a composition that comprises a radioactive [18F], [76Br]-, [77Br]-, [211At]-, [123I], [125I], or [131I]-N-radioistope-labeled-aryl-alkyl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer... Agent: Edward T. Wei

20070053835 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070053836 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the... Agent: Mchale & Slavin, P.a.

20070053838 - Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20070053837 - Radiopharmaceuticals for cancer diagnosis and treatment: Radionuclide labelled conjugates based on substance P and analogues thereof with the chelator (DOTAGA) (1-(1-rarboxy-3-carboxy-propyl)-4,7,10(carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane, DOTASA (1-(1-carboxy-2carboxy-ethyl)-4,7,10(carboxymethyl)1,4,7,10-tetraazacyclo-dodecane, or chelator (DOTA) [1,4,7,10 tetraazaacyclo-dodecane 1,4,7,10-tetra(acetic acid)] are useful radiopharmaceutical substances for targeting and treatment of brain tumors, especially gliomas.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070053839 - Directing cells to target tissues organs: The invention provides for methods of directing cells to a damaged tissue or organ in an individual, and further provides for methods of monitoring such cells in the individual. The invention also provides compositions for tagging cells such that the cells can be directed to the damaged tissue or organ.... Agent: Fish & Richardson P.c.

20070053840 - Multi dtpa conjugated tetrapyrollic compounds for phototherapeutic contrast agents: Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e.g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3... Agent: Simpson & Simpson, Pllc

20070053841 - Use of 1,1,1,2-tetrafluoroethane for measuring lung function, especially for determining the functional residual capacity (frc) of the lungs: 1,1,1,2-Tetrafluoroethane (norflurane) is used as a tracer/trace gas for measuring the lung function because of its simple detectability, physiological harmlessness, environmental friendliness and ready availability. Especially advantageous is the possibility of the optical concentration measurement of 1,1,1,2-tetrafluoroethane for the measurement of the lung function and especially for the determination of... Agent: Mcglew & Tuttle, Pc

20070053846 - Dry coating and downstream processing of cohesive powders: The present disclosure is directed to systems and methods for dry particle coating of cohesive powders, and to the dry coated particles/powders produced thereby. The present disclosure is further directed to systems and methods for dry coating of cohesive particles, particularly nanosized particles, to provide enhanced flowability and other advantageous... Agent: Mccarter & English, LLP Attn: Basam E. Nabulsi

20070053844 - Formulations for alteration of biophysical properties of mucosal lining: Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070053843 - Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same: Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and lactose anhydrate.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070053842 - Method of engineering particles for use in the delivery of drugs via inhalation: The present invention provides a method for engineering particles for use in the delivery of drugs via inhalation and involves the use of an artificial respiratory airway that simulates a mammalian lung system to create an environment in which particles can be engineered. The method utilizes the inhalation flow rate... Agent: Dennison, Schultz & Macdonald

20070053845 - Nanocell drug delivery system: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may... Agent: Choate, Hall & Stewart LLP

20070053847 - Styling wax composition: The present invention relates to styling wax composition applied as aerosol spray with improved styling benefits, especially with excellent shine and hold and also excellent elasticity. The inventors of the present invention have found out surprisingly that an aqueous or aqueous-alcoholic hair styling composition based on at least one film... Agent: Norris, Mclaughlin & Marcus, P.a.

20070053848 - Antimicrobial materials for dental care applications: The invention pertains to antimicrobial dental care materials. In particular, the invention pertains to antimicrobial dental care materials containing biocidal complexes, e.g.: a) a mouthwash containing said complex; b) a dentifrice containing said complex; c) a dental floss coated and/or impregnated with said complex; and d) a protective coating for... Agent: Law Offices Of Jack Matalon

20070053849 - Oral care compositions containing combinations of anti-bacterial and host-response modulating agents: The present invention encompasses topical oral care compositions comprising the combination of an anti-bacterial agent with an anti-inflammatory agent in an orally acceptable carrier for effective treatment and prevention of bacteria-mediated diseases and conditions in the oral cavity and for modulating host reaction to bacterial pathogens present in the oral... Agent: The Procter & Gamble Company Intellectual Property Division

20070053850 - Aqueous sanitizers, disinfectants, and/or sterilants with low peroxygen content: The present invention is drawn to disinfectant compositions, which are human safe, e.g., food grade or food safe. In one embodiment, an aqueous disinfectant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 10.0 wt % of a peroxygen, and an alcohol. Additionally, from 0.001 ppm... Agent: Thorpe North & Western, LLP.

20070053851 - Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances: The present invention relates to an agent with oral activity on the form of a toothpaste, a mouthwash or a mouthwash concentrate containing one or more substances sensitive to oxidation, characterised in that the agent has a water content according to Karl Fischer of 7.5 wt.-% or less.... Agent: Stephen M Haracz Bryan Cave

20070053854 - Cosmetic compositions: e

20070053852 - Lipidic protein-transfer systems and cosmetic/dermatological use thereof: The present invention relates to compositions having bioactive transfer proteins in stable carrier systems. Such systems are above all suitable for influencing/changing lipid cell structures by means of improved lipid exchange, while at the same time having great stability. In this connection, not only transfer proteins and lipid components, but... Agent: William Collard Collard & Roe, P.c.

20070053853 - Personal care compositions with silicones and dihydroxypropyl trialkyl ammonium salts: A personal care composition is provided with a silicone compound and being aesthetically modified for improved skinfeel with a quaternary ammonium salt, the salt having a structure AB, wherein A is a cationic charged component, B is an anionic charged component, and A has one quaternized nitrogen atom, at least... Agent: Unilever Intellectual Property Group

20070053855 - Personal care products incorporating cellulosic fatty acid esters: Cellulose ester compounds and compositions that include such cellulose ester compounds dissolved in lipophilic solvents.... Agent: William K. Mcgreevey Eastman Chemical Company

20070053856 - Integrating ultraviolet exposure detection devices: Devices or formulations incorporating photochromic agents and methods of using them are provided. The compositions are useful in connection with personal care, light and/or ultraviolet radiation detection, imaging and printing applications.... Agent: Bozicevic, Field & Francis LLP

20070053857 - Peptide-based conditioners and colorants for hair, skin, and nails: Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants based are described. The peptide-based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070053858 - Personal care composition: Personal care composition comprising a vitamin B3 compound, a sugar amine, a hydroquinone compound, and a dermatologically-acceptable carrier.... Agent: The Procter & Gamble Company Intellectual Property Division

20070053859 - Compostions containing silicone polymer, wax and volatile solvent: The invention relates to compositions containing at least one polyorganosiloxane-containing polymer, at least one volatile non-silicone oil, at least one alkylene polymer wax, at least one silicone film-forming agent and, optionally, at least one long-chain alcohol wax, at least one coloring agent, and/or at least one volatile silicone oil, as... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070053860 - Short-chain enol esters as odiferous substance precursors: e

20070053861 - Ophthalmic composition for contact lens: Disclosed are; a method for suppressing adsorption of a refreshing agent and/or chlorobutanol by a contact lens in an aqueous ophthalmic composition for contact lens containing a refreshing agent and/or chlorobutanol, as well as for suppressing pH decline due to degradation of chlorobutanol, wherein the method comprises preparing the composition... Agent: Merchant & Gould Pc

20070053863 - Cosmetic composition comprising extract form mallotus japonicus for improving skin wrinkle: The present invention relates to compositions for inhibiting elastase activity, enhancing collagen biosynthesis and improving skin wrinkle, comprising Mallotus japonicus extract as active ingredient. The present compositions exhibit the inhibition effect on elastase activity and promotion effect on collagen biosynthesis at a molecular level, and as a result, excellent efficacy... Agent: Nixon & Vanderhye, Pc

20070053862 - Monoi butter, novel cosmetic and/or dermatological compositions comprising monoi butter and uses thereof: Life's necessities, more particularly to cosmetics, hygiene and dermatology. The invention more specifically relates to a novel active cosmetic ingredient, a hydrogenated Monoï derivative, preferably from Tahiti, known as Monoï butter, having improved texture and a moisturizing, protecting, sanitizing, smoothing and softening effect. The invention also relates to the use... Agent: Hedman & Costigan P.c.

20070053866 - In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives: The invention provides coating compositions that comprise antimicrobial agent comprising at least one hydroxy analog of methionine and a binder. The antimicrobial agents may be used as preservatives to inhibit a broad spectrum of microorganisms in the coating compositions.... Agent: Polsinelli Shalton Welte Suelthaus P.c.

20070053867 - Polymers and polymer coatings: The invention provides polymers, methods of preparing polymers, and compositions that include polymers, wherein said polymers include a plurality of two-carbon repeating units in a polymer chain, wherein one or more of the two-carbon repeating units of the polymer chain have a substituent that is covalently bonded to a semifluorinated... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20070053865 - Poly(potassium and sodium styrene sulfonate) its manufacture and its uses: Antibiotic-associated diarrhea, such as that caused by Clostridium difficile, represents a serious medical complication that can result from administering a broad-spectrum antibiotic to a subject. Such diarrhea leads to significant potassium loss from the subject. The present invention discloses a polymeric therapeutic agent that treats antibiotic-associated diarrhea and is physiologically... Agent: Genzyme Corporation Legal Department

20070053864 - Poly(potassium and sodiumstyrene sulfonate) its manufacture and its uses: Antibiotic-associated diarrhea, such as that caused by Clostridium difficile, represents a serious medical complication that can result from administering a broad-spectrum antibiotic to a subject. Such diarrhea leads to significant potassium loss from the subject. The present invention discloses a polymeric therapeutic agent that treats antibiotic-associated diarrhea and is physiologically... Agent: Attention: Christopher M. Beck Legal Department

20070053869 - Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents: The present invention relates to a method of enhancing absorption of a pharmaceutical agent by administering the agent in combination with an inhibitor of BCRP/ABCG2 wherein the amount of the inhibitor is about the critical micelle concentration of the inhibitor or less than the critical micelle concentration. The invention also... Agent: Rosemary M. Miano Warner-lambert Company Llc

20070053868 - Solvent system for enhancing the solubility of pharmaceutical agents: Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070053871 - Pharmaceutical formulations: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.... Agent: Marshall, Gerstein & Borun LLP

20070053870 - Polysaccharide-functionalized nanoparticle, drug delivery system for controlled release comprising the same and preparation method thereof: The present invention provides a polysaccharide-functionalized nanoparticle, a drug delivery system for controlled release comprising the nanoparticle and a preparation method thereof. In particular, the nanoparticle of the present invention comprises a core of a biodegradable polymer, an outer hydrogel layer of a biocompatible polymer emulsifier and a polysaccharide physically... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20070053873 - Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith: A treatment for tumorous canines and a method of preparing, cultivating, and cryogenically preserving the pharmaceutical formulation used in the treatment. Canine lymphocytes are activated and expanded in the presence of a combination of anti-canine CD3 antibodies and interleukin-2 (IL-2) (preferably anti-canine CD3 antibodies and human interleukin-2 (human IL-2)) and... Agent: Greenblum & Bernstein, P.L.C

20070053875 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053874 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053872 - Treatment of wounds using il-17b: IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053877 - Methods of treating idiopathic pulmonary fibrosis: The present application provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF, and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.... Agent: Marshall, Gerstein & Borun LLP

20070053878 - Sars: The invention relates to the field of virology. The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus (SARS) within the group of coronaviuses and components thereof.... Agent: Hoffmann & Baron, LLP

20070053879 - Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator: Disclosed are full length isolated DNAs encoding cystic fibrosis transmembrane conductance regulator (CFTR) protein and a variety of mutants thereof. Also disclosed are antibodies specific for various CFTR domains and methods for their production. Expression of CFTR from cells transformed with these CFTR genes or cDNAs demonstrate surprising CFTR intracellular... Agent: Genzyme Corporation Legal Department

20070053880 - Growth differentiation factor-16: Growth differentiation factor-16 (GDF-16) is disclosed along with its polynucleotide sequence and amino acid sequence Also disclosed are diganostic and therapeutic methods of using the GDF-16 polypeptide and polynucleotide sequences.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Rudnick Gray Cary Us LLP

20070053890 - Canine embryonic stem cells: The invention relates to canine embryonic stem cells, methods of cultivation and propagation of the cells, and production of differentiated cells. The embryonic stem cells may be obtained by isolating a canine embryo, culturing the embryo in the presence of a feeder layer and one or more proliferation agent, removing... Agent: Merchant & Gould Pc

20070053889 - Il-10 gene transfer to peripheral mononuclear cells: The present invention to methods for producing mononuclear cells overexpressing IL-10. The method comprises the ex vivo introduction of an expression construct comprising a nucleotide sequence encoding a polypeptide having IL-10 activity into peripheral blood mononuclear cells of a subject. The thus obtained peripheral blood mononuclear cells have an altered... Agent: Mckenna Long & Aldridge LLP

20070053891 - Snail, a new marker for tumour invasion and target protein of new antitumoral compounds: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of... Agent: Dann, Dorfman, Herrell & Skillman

20070053882 - Method for producing microorganism agent: The present invention provides a method for producing a microorganism agent to be used in biocontrol and prevent plant from suffering the disease. The method is to provide a microorganism for working on an object, combine the microorganism with a modeling material to form an intermediate, and add a modeling... Agent: The Webb Law Firm, P.c.

20070053886 - Biological bypass bridge with sodium channels, calcium channels and/or potassium channels to compensate for conduction block in the heart: This invention provides a bypass bridge comprising a tract of gap junction-coupled cells having a first end and a second end, both ends capable of being attached to two selected sites in a heart so as to allow the conduction of a pacemaker and/or electrical signal/current across the tract between... Agent: Kenyon & Kenyon LLP

20070053885 - Mesenchymal stem cell: It is intended to obtain a mesenchymal stem cell in the early stage of differentiation from a pluripotent stem cell differentiated in vitro. A mesenchymal stem cell is obtainable by: a) the step of culturing pluripotent stem cells, b) the step of confirming the appearance of a cell with stroma... Agent: Sterne, Kessler, Goldstein & Fox Pllc

20070053887 - Method for production of neuroblasts: A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Us LLP

20070053883 - Neuronal cell lineages and methods of production thereof: Methods are provided in which a sterol-depleting agent such as β-cyclodextrin (βCD), is used to modulate signaling by a differentiation signaling protein such as Hedgehog protein or a BMP in vitro. As illustrated herein, the use of βCD in conjunction with Sonic Hedgehog N-terminal peptide (ShhN) causes substantially all of... Agent: Dla Piper Us LLP

20070053884 - Novel adult tissue-derived stem cell and use thereof: Subjects of the present invention are to establish a technology for separating, isolating and culturing a stem cell derived from adult tissue while retaining the in vivo properties thereof, and to provide a preventive and/or therapeutic agent for diseases which accompany tissue injury, which comprises a stem cell derived from... Agent: Fitzpatrick Cella Harper & Scinto

20070053888 - Use of umbilical cord blood to treat individuals having a disease, disorder or condition: The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and... Agent: Jones Day

20070053893 - Method of reducing immunological tolerance to malignancy: Disclosed are therapeutic formulations comprising myristoylCoA and N-myristoyl transferase and methods of using such formulations to stimulate the immune system of a mammal afflicted with carcinoma and having a detectable blood level of unacylated A-protein to produce an immune response thereto. Also disclosed are methods of treating an A-protein displaying... Agent: Ann-louise Kerner, Ph.d. Lappin & Kusmer

20070053892 - Methods and kits for co-administration of nutritional supplements: The present invention relates to methods of co-administration of various vitamin, mineral and aspirin compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B6, vitamin B12, folic acid, and CoQ10 and a second composition comprising aspirin for nutritional supplementation and drug therapy in order to prevent, treat... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070053894 - Compound and method for regulating plasminogen activation and cell migration: The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular,... Agent: Birch Stewart Kolasch & Birch

20070053895 - Method of treating and diagnosing parkinsons disease and related dysautonomic disorders: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease... Agent: Maine & Asmus

20070053896 - Diagnostic marker for ovarian cancer: The present invention relates to methods of detecting, monitoring the efficacy of treatment of, and assessing the severity of ovarian cancer, by assessing the concentration of haptoglobin-1 precursor in a sample of biological fluid. The invention also relates to a kit comprising an antibody or nucleic acid probe specific for... Agent: Jennifer M Mccallum, Ph D, Esq The Mccallum Law Firm, Llc

20070053897 - Calcium independent cytosolic phospholipase a2/b enzymes: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.... Agent: Wyeth/finnegan Henderson, LLP

20070053898 - Method for reducing allergencity in indoor spaces: According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats... Agent: Hunton & Williams LLP Intellectual Property Department

20070053899 - Activated carbon and use thereof for reducing or maintaining body weight: The present invention is generally directed towards compositions including activated carbon and methods of use thereof such as for reducing or maintaining body weight in a subject. In one embodiment, a dietary supplement comprising a composition including amorphous activated porous carbon particles, with a total surface area not less than... Agent: Wood, Herron & Evans, LLP

20070053900 - High concentration antibody and protein formulations: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders... Agent: Genentech, Inc.

20070053901 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Robin M. Silva, Esq. Dorsey & Whitney LLP

20070053902 - Anti-alphabeta3 humanized monoclonal antibodies: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070053904 - Antibodies having diagnostic, preventive, therapeutic, and other uses: The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules,... Agent: Millennium Pharmaceuticals, Inc.

20070053903 - Methods of using phhla2 to co-stimulate t-cells: The invention provides pHHLA2 co-receptor polypeptides and functional fragments, antibodies to same, isolated polynucleotides encoding same, vectors containing the polynucleotides, cells containing the vectors. Methods of making and using these co-stimulatory pHHLA2 co-receptors molecules are also disclosed.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053905 - Agent for treating chondroma and chondrosarcoma: The present invention relates to a novel agent for treating chondroma and chondrosarcoma containing a substance which inhibits binding of parathyroid hormone related peptide to its receptor for improving the prognosis of chondroma or chondrosarcoma.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070053906 - Liquid formulations of tumor necrosis factor-binding proteins: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070053909 - Method of treating fibrosis: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf3 antagonist is an antibody that... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053907 - Uses of human zven antagonists: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods of using antagonists to Zven1 and Zven2 to treat inflammation in the intestine.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053908 - Uses of human zven antagonists: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods of using antagonists to Zven1 and Zven2 to treat inflammation in the intestine.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053912 - Compounds for neutralizing the effects of secreted pla2iia: A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body... Agent: Jacobson Holman Pllc

20070053911 - Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2): The invention provides a human PAR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, neurological... Agent: Banner & Witcoff

20070053913 - Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2): The invention provides a human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases,... Agent: Jeffrey M. Greenman

20070053910 - Modulation of s6 kinase activity for the treatment of obesity: This invention provides screening methods for agents effective in treating obesity through specific inhibition of S6 kinase 1 activity. Also provided are methods of treating obesity by administering an effective amount of an inhibitor specific for S6 kinase 1.... Agent: Novartis Corporate Intellectual Property

20070053914 - Antitumor antibodies, proteins, and uses thereof: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.... Agent: Lahive & Cockfield, LLP

20070053915 - Gips, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein: The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070053916 - Replikin peptides in rapid replication of glioma cells and in influenza epidemics: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.... Agent: Kenyon & Kenyon LLP

20070053917 - Composition and method for the treatment and prevention of enteric bacterial infections: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a... Agent: Michael L Goldman Nixon Peabody

20070053919 - Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions: A composition for eliciting a T-cell mediated immune response in a subject includes transfer factor from at least two different types of source animals. For example, the composition may include mammalian transfer factor and nonmammalian transfer factor. An example of the composition includes a combination of a colostrum-derived product, which... Agent: Trask Britt

20070053918 - Injectable depots consisting of liposomal aggregates for the delivery of active substances: The invention relates to formulations of liposomes and polymers for the production of an injectable depot of active substances, which has sustained release and effect in a mammal organism.... Agent: Norris, Mclaughlin & Marcus, P.a.

20070053920 - Nematode polypeptide adjuvant: The invention relates to a set of novel immunological adjuvants based upon so called “polyladder” proteins of nematode worms. These proteins are typified by repeating units separated by a protease cleavage motif of RX(K/R)R or RXFR where R is ariginine, X is any amino acid, K is lysine and F... Agent: Klarquist Sparkman, LLP

20070053921 - Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20070053922 - Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and... Agent: Sterne, Kessler, Goldstein & Fox Pllc

20070053923 - Dna vaccine composition with enhanced immunogenicity: Disclosed is a vaccine composition that includes a peptide adjuvant, and a DNA vaccine encoding an immunogenic protein. Also, the present invention discloses a method of enhancing immune responses, which is based on the administration of the vaccine composition.... Agent: Tanya A Arenson Medlen & Carroll

20070053926 - Antigenic neisserial peptides: WO99/24578 discloses a large number of proteins from Neisseria meningitidis and Neisseria gonorrhoeae. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed.... Agent: Chiron Corporation Intellectual Property - R440

20070053927 - Chlamydia pneumoniae polynucleotides and uses thereof: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070053924 - Conserved and specific streptococcal genomes: The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which are conserved or specific to one or more of the species of S. pneumoniae (“pneumococcus” or “S.... Agent: Novartis Vaccines And Diagnostics Inc.

20070053925 - Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation: The Efb protein from Staphylococcus aureus has now been shown to have the ability to bind to the C3 protein which is a crucial component in the activation of complement, and a specific C3 binding region has been located at the C-terminal end of the Efb protein. Isolated proteins and... Agent: Stites & Harbison Pllc

20070053928 - Compounds useful in the diagnosis and treatment of pregnancy-associated malaria: The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic... Agent: Foley And Lardner LLP Suite 500

20070053929 - Marine algae extract and lipase inhibitor containing the same: A lipase inhibitor comprising as an active ingredient an extract of Ascophyllum nodosum which is a kind of brown algae can be used as a useful healthy food or food for specified health uses for the treatment and/or prevention of obesity or hyperlipemia.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070053930 - Combination therapy for treatment of high cholesterol: Compositions and convenient methods for the delivery of a therapeutic combination of statins such as mevinolin, with niacin and ginkgo to patients with high blood cholesterol are provided.... Agent: Heller Ehrman White & Mcauliffe LLP

20070053931 - Dietary supplements for treating hypertension: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to treat hypertension (e.g., lower blood pressure) in a subject (e.g., a mammal) as a result of having been cultured in the presence of an alternating electric field having a specific frequency... Agent: Fish & Neave Ip Group Ropes & Gray LLP

20070053932 - Methods and compositions for reducing odor: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells have been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength for a period of time sufficient to substantially increase the capability of said plurality of yeast cells... Agent: Fish & Neave Ip Group Ropes & Gray LLP

20070053933 - Il28 and il29 truncated cysteine mutants and antiviral methods of using same: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070053934 - Polyvalent multimeric composition containing active polypeptides, pharmaceutical compositions and methods of using the same: The invention is directed to compositions comprising polyvalent complexes containing a biocompatible polymer backbone to which is attached a plurality of monomeric anti-microbial peptides and to methods for using such complexes to stabilize anti-microbial peptides for treating or preventing a disease or condition resulting from infection with a microbe. Multivalent... Agent: Klauber & Jackson

20070053935 - Subunits of the adenovirus fiber protein and uses thereof as vaccines: The present invention relates to a nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, particularly, of the avian adenoviruses HEV or EDS. This sequence comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The invention further provides for... Agent: Cooper & Dunham, LLP

20070053936 - Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Drinker Biddle & Reath (dc)

20070053937 - Antigen of hybrid m protein and carrier for group a streptococcal vaccine: Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes that encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.... Agent: Seed Intellectual Property Law Group Pllc

20070053938 - Virulence of streptococci: The invention relates to the field of diagnosis of and vaccination against Streptococcal infections and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus, the method comprising modifying a genomic fragment of Streptococcus wherein the genomic fragment comprises at least... Agent: Trask Britt

20070053939 - Biguanide drug-containing jelly preparation: The invention provides a biguanide drug-containing jelly preparation of which discomfort upon administration is decreased by the control of its harshness or bitterness. In addition, the preparation has stability and excellent ability for releasing a drug in the digestive tract. The biguanide drug-containing jelly preparation of the invention is characterized... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070053940 - Method of measuring the efficacy of a skin treatment program: The present invention includes a method of measuring the efficacy of a skin treatment program on human skin. The method comprises: a. accessing a multiplicity of photographic images of human faces, each image having associated with it a chronological age of the human whose likeness it captures; b. assessing the... Agent: Philip S. Johnson Johnson & Johnson

20070053945 - Composition and method for killing insects: Disclosed is a method for protecting a tree from insects by injecting the tree with a fungicide and/or an antibiotic, and applying a composition to the surface of the tree, said composition comprising water, an insect repellent, an antihistamine, and an insect poison.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070053944 - Concentrated suspensions: Novel suspension concentrates comprising a) at least one active compound, solid at room temperature, from the group of the azoles and/or the strobilurins, b) at least one penetration enhancer from the group of the alkanolethoxylates, c) at least one dispersant from the group of the polymers of methyl 2-methyl-2-propenoate and... Agent: Bayer Cropscience Lp Patent Department

20070053943 - Dimethicone-containing sustained release injection formulation: A sustained release formulation by using dimeticone as the dispersion medium, which includes active ingredient (e.g., drugs against parasites, insecticides, NSAIDs, antibiotics, sex hormone like agents or oily soluble vitamins) and dimeticone as the medium. Suitable stabilizer, antioxidant, local analgesics and material for sustained release may be added. The formulation... Agent: Contour Semiconductor, Inc.

20070053942 - Disinfectant and/or bactericidal aqueous compositions: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt, and at least one polyoxyethylene-based nonionic surfactant selected from the group consisting of polyoxyethylene higher alkyl ethers and polyoxyethylene alkylphenyl ethers; a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt at... Agent: Sughrue Mion, Pllc

20070053946 - Hydrophilic coating: An antimicrobial coating slurry includes about 15.5 wt % of a wetting agent, about 6.0 wt % of an insolubilizer, about 1.1 wt % of a biocide agent, and about 7.8 wt % of an inorganic material that includes lithium oxide and the balance water. The slurry is applied to... Agent: Carlson, Gaskey & Olds, P.c.

20070053948 - Lens care solution demonstration kit: A demonstration kit and method for marketing lens care solution. The kit contains two demonstrations. One demonstration is directed to lubricity and the other demonstration is directed to protein stabilization. The protein assay uses a solution of urea.... Agent: Bausch & Lomb Incorporated

20070053949 - Lubricious coating: A lubricant coating vehicle for medical devices used to reduce the coefficient of friction of such devices upon exposure thereof to moisture. The lubricant coating vehicle allows the introduction of a pharmacological additive having a release rate that is within acceptable pharmacokinetic criteria. The release rate is adjusted by utilizing... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070053947 - Non-toxic molluscicidal, bryophoticidal and algicidal composition: A non-toxic, environmentally safe and biodegradable composition having molluscicidal, Bryophytocidal and algicidal properties is disclosed.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20070053941 - Vermin repellent: A method for repelling a pest using 2-isopropyl-3-methoxi-pyrazine as a pest repellent, particularly a mole repellent, and a pest repelling composition which comprises this compound.... Agent: Bacon & Thomas, Pllc

20070053950 - Composition of polymer microcapsules of biocide for coating material: The invention provides composition comprising microcapsules containing biocides for coating material such as paint. The invention describes composition of microcapsules containing biocides, especially Irgarol (algaecide) and Zinc Pyrithione (fungicide) and coating material such as paint to increase the life of coating material from the attack of algae and fungi respectively.... Agent: Luedeka, Neely & Graham, P.c.

20070053951 - Composite biomaterial for bone implants: Biomaterials for bone implants constituted by an inorganic phase formed by calcium salts, mainly phosphates, hydroxy- and carbonate-apatite and an organic phase formed by polymers obtained from vinyl acetate and crotonic acid. These biomaterials can be dense or porous and present different speeds of resorption when they are used as... Agent: Axios Law Group

20070053953 - Method of loading beneficial agent to a prosthesis by fluid-jet application: An interventional device for delivery of beneficial agent to a lumen and methods of loading and manufacture of the same, which include a prosthesis loaded with beneficial agent to provide a controlled dosage concentration of beneficial agent to the lumen. The beneficial agent is loaded onto the prosthesis by a... Agent: Robert Deberardine Abbott Laboratories

20070053952 - Nitric oxide-releasing polymers derived from modified polymers: Modified polyimines and derivatives thereof suitable as implantable medical devices and coatings therefore are provided. Specifically, implantable medical devices and/or coatings comprise amphiphilic polymers derived from modified polyimines. The medical devices and coatings of the present invention can also be used for in situ nitric oxide release/controlled release drug delivery... Agent: Medtronic Vascular, Inc. Ip Legal Department

20070053954 - Macromer-melt formulations: The invention provides methods and articles for the administration of a biologically active substance (BAS). These methods and articles provide for the controlled and sustained delivery of relatively large quantities of these substances with a low burst effect. The articles made using the method of the invention have increased percentages... Agent: Clark & Elbing LLP

20070053955 - Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain: Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070053956 - Food formulation for aquatic animals with integrated targeted delivery of bioactive agents: An encapsulated formulation for food and bioactive agent delivery to aquatic animals includes various combinations of nutrients, a digestion enhancer, bioactive agents, and a local absorption enhancer. The bioactive agents and absorption enhancer may be encapsulated within a delay layer for targeted release at an area of the digestive tract... Agent: Dr. Mark Friedman Ltd. C/o Bill Polkinghorn

20070053957 - Agents for controlling biological fluids and methods of use thereof: Therapeutic formulations adapted for positive-pressure application for controlling biological fluid at a desired site in a subject, absorbent articles comprising therapeutic formulations, and anti-infective devices coated with therapeutic formulations, said formulations comprising about 25% to about 99% by weight liquid-crystal forming compound and 0% to about 75% by weight solvent.... Agent: Bromberg & Sunstein LLP

20070053959 - Anti-perspirant/deodorant peel-on strip: Anti-Perspirant/Deodorant Peel-On Strip is a strip with a protective film, adhesive layer, and a layer of deodorant and/or antiperspirant. The strip is ideally sealed inside a foil or other moisture resistant package. A user tears the top off of the package containing the strip and removes it from the package.... Agent: Galasso & Associates, Lp

20070053958 - Elastomeric gloves and methods of making: Elastomeric film-like products such as natural latex gloves are coated with novel lubricity compositions and compositions which protect the skin of the wearer from certain undesirable medical conditions. In powder-coated gloves, the coating composition comprises rice starch, and optionally USP-grade colloidal oatmeal in pharmaceutically accepted concentration. In powder-free gloves, the... Agent: Martin & Associates, Llc

20070053961 - Diagnostic markers of wound infection ii: The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least on angiogenic factor in a sample of wound fluid. The preferred angiogenic growth factors are angiogenin and vascular endothelial growth factor (VEGF).... Agent: Philip S. Johnson Johnson & Johnson

20070053962 - Diagnostic markers of wound infection iii: The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one cell surface receptor in a sample of wound fluid. The preferred cell surface receptors are Intercellular adhesion molecule-1 (ICAM 1) and... Agent: Philip S. Johnson Johnson & Johnson

20070053960 - Multiribbon nanocellulose as a matrix for wound healing: The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a... Agent: Chalker Flores, LLP

20070053963 - Drug delivery to a joint: A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070053964 - Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist: A percutaneous absorption type ophthalmic preparation comprising muscarinic receptor agonist is prepared, which can promote lacrimal fluid secretion by administration to the skin surface of the eyelid, and which causes fewer side effects such as miosis, thereby to provide a percutaneous absorption type ophthalmic preparation capable of maintaining a therapeutically... Agent: Blakely Sokoloff Taylor & Zafman

20070053969 - Device for treating and promoting healing of damaged body tissue: A device for treating and promoting healing of damaged body tissue. The device comprises an encapsulating device disposed adjacent the damaged tissue for controlling the environmental conditions surrounding the tissue. A transfer device is disposed on the encapsulating device to allow at least one of a predetermined medium to communicate... Agent: James Ray & Associates

20070053965 - Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation: A kit comprising a plaster, which contains a pharmaceutical active ingredient and is designed to administer the active ingredient transdermally to a human or animal to which the plaster is applied, and an agent that is separate from the plaster and at least reduces skin irritation from the plaster.... Agent: Crowell & Moring LLP Intellectual Property Group

20070053966 - Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue: A system and method for treating damaged musculoskeletal tissue includes an orthopedic support structure and a nitroglycerin-containing composition. The orthopedic support structure provides mechanical support to the damaged tissue and maintains the nitroglycerin-containing composition in contact with the skin of a subject wearing using the system. The nitroglycerin-containing composition can... Agent: Thorpe North & Western, LLP.

20070053967 - Percutaneous absorption-type pharmaceutical preparations: A percutaneous absorption-type pharmaceutical preparation containing a sublimation drug is provided, where from a plaster layer, a drug is released as volatile substance with a lapse of time, but the released drug has no adverse effect on the handling of the preparation, and the quality of the preparation is maintained... Agent: Sughrue-265550

20070053968 - Transdermal drug delivery devices containing o-desmethyl venlafaxine (odv) or its salts: The present invention provides transdermal drug delivery devices (i.e., patches) comprising O-desmethylvenlafaxine (ODV), a selective serotonin and norepinephrine re-uptake inhibitor, or a pharmaceutically acceptable salt thereof, which, among other, offer the advantage of eliminating or reducing the adverse side effects associated with the oral administration of ODV. Also provided are... Agent: Choate, Hall & Stewart LLP

20070053971 - Antimicrobial and antiviral compounds and methods for their use: The present invention provides protonated compounds having antiviral and antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi. The invention also provides antiviral compositions comprising compounds of... Agent: Wilson Sonsini Goodrich & Rosati

20070053970 - Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway: The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in... Agent: Brooke Schumm Iii

20070053972 - Gelatin capsules containing actives: Gelatin capsules are surface treated with compositions which provide enhanced protection to the actives within by imparting one or more properties such as increased hardeners to the gelatin shell, an enhanced protective barrier or enhanced organoleptic perception to the consumer.... Agent: Hoffmann & Baron, LLP

20070053973 - Amorphous antibiotic composition comprising cefditoren pivoxil: According to the present invention, there is provided a solid dispersion composition which can maintain amorphous cefditoren pivoxil in a suspension for a long period of time. The present invention is a solid dispersion composition comprising at least 0.1 mg of a sugar ester fatty acid on the basis of... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070053977 - Calcium carbonate granulation: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet... Agent: King & Spalding

20070053976 - Novel combination of drugs as antidepressant: A novel antidepressant composition of a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is disclosed, which has a significantly high therapeutic effect as compared with conventional antidepressants. The therapeutic method using a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or... Agent: Venable LLP

20070053978 - Process for co-spray drying liquid herbal extracts with dry silicified mcc: A process for preparing dry extracts from a liquid extract and at least one additional substance by a spray-drying process, characterized in that said at least one additional substance is added to the spray-drying process in a dry form during the spray-drying processes.... Agent: Davidson, Davidson & Kappel, Llc

20070053975 - Ramipril formulation: A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect.... Agent: Sterne, Kessler, Goldstein & Fox Pllc

20070053974 - Stable oral composition: The present invention provides a stable oral composition comprising a therapeutically effective amount of desloratadine and a stabilizer selected from the group comprising an antioxidant, a pharmaceutically acceptable organic compound that provides an alkaline pH, an alkali metal salt, or mixtures thereof, and pharmaceutically acceptable excipients.... Agent: Merchant & Gould Pc

20070053979 - Controlled release formulation of erythromycin derivatives: The present invention is directed to a controlled release formulation in tablet form comprising a pharmaceutically effective amount of an erythromycin derivative and a lubricating effective amount of a lubricant in the absence of material selected from the group consisting of alginic acid or salts thereof or hydrophilic sustained release... Agent: Scully, Scott, Murphy & Presser

20070053980 - Extended release tiagabine formulations with reduced side-effects: Extended release tiagabine formulations that demonstrate fewer side-effects when administered to a patient.... Agent: Robert Deberardine Abbott Laboratories

20070053981 - Solid composition comprising a proton pump inhibitor: The present invention related to a method for oral administration of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners capable of forming a... Agent: White & Case LLP Patent Department

20070053982 - Sustained release oral formulations: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.... Agent: Novartis Corporate Intellectual Property

20070053985 - Coenzyme q10-containing fine particle with excellent dispersibility: The present invention has an object to provide coenzyme Q10-containing particles, which can be easily and simply dispersed into water without any surfactants or other additives, and their production method. The present invention makes it easier to prepare an aqueous dispersion containing coenzyme Q10, which is hard to disperse in... Agent: Sughrue Mion, Pllc

20070053983 - Extended release compositions of metoprolol succinate: The present invention relates to sustained release solid pharmaceutical composition comprising antihypertensives, in particular, Metoprolol succinate or pharmaceutically acceptable derivatives thereof and a process for preparing such a formulation. The present invention is a composition comprising Metoprolol succinate or its pharmaceutically acceptable derivatives thereof and the composition releases the drug... Agent: Bio Intellectual Property Services (bio Ips) Llc

20070053984 - Topical gels compositions: Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is... Agent: Frost Brown Todd, Llc

20070053986 - System for the liberation of an active principle and its use: A local system for the liberation of an active principle is described which consists of spherical bodies which are composed of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate and, if necessary, zirconium dioxide and/or barium sulphate and a pharmaceutical active principle, which contains at least one hemostyptically effective compound stable... Agent: Norris, Mclaughlin & Marcus, Pa

20070053987 - Cross-linked polysacharide and protein matrices and methods for their preparation: Methods for preparing cross-linked polysaccharide matrices by cross-linking one or more amino group containing polysaccharides or amino-functionalized polysaccharides with reducing sugars and/or reducing sugar derivatives. The resulting matrices may include polysaccharide matrices and composite cross-linked matrices including polysaccharides cross-linked with proteins and/or polypeptides. Additives and/or cells may also be included... Agent: Daniel J Swirsky

20070053989 - Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents: This invention is directed to an apparatus and method for producing microparticles comprising pharmacologically active agents and biodegradable polymers. The apparatus includes a spinning disk containing a reservoir in the center thereof and a flat inclined surface. The apparatus optionally includes serrations and/or a flat surface beneath the periphery of... Agent: Ross Spencer Garsson Winstead Sechrest & Minick P.c.

20070053988 - Monodispersed solid lipid particle compositions: A composition includes a monodispersed lipid phase which is dispersed in a continuous aqueous phase, wherein the lipid phase includes at least one crystallizable lipid, at least one active ingredient and at least one compound including two chains of fatty acids and one glycol polyethylene chain. A method for the... Agent: Young & Thompson

20070053990 - Pharmaceutical formulations exhibiting improved release rates: This invention is directed to an apparatus and method for producing microparticles comprising pharmacologically active agents and biodegradable polymers. The apparatus includes a spinning disk containing a reservoir in the center thereof and a flat inclined surface. The apparatus optionally includes serrations and/or a flat surface beneath the periphery of... Agent: Ross Spencer Garsson Winstead Sechrest & Minick P.c.

20070053991 - Cartilage-derived morphogenetic proteins: Nucleotide and amino acid sequences of cartilage-derived morphogenetic proteins (CDMP-1 and CDMP-2) from human and bovine cartilage extracts. These proteins exhibit chondrogenic activity and can be used to repair cartilage defects in a mammal.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070053992 - Inhalable gaseous medicament based on xenon and nitrous oxide: The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors... Agent: Air Liquide

20070053993 - Method to predict and prevent oxygen-induced inflammatory tissue injury: Methods for modulating responsiveness to increased oxygen levels in an at-risk subject identifying an at-risk subject; and before exposing the identified at-risk subject to an increased amount of oxygen, administering to the at-risk subject an anti-inflammatory agent wherein the responsiveness of the at-risk subject to said increased amount of oxygen... Agent: Elmore Patent Law Group, Pc

20070053994 - Anti-inflammatory treatment: The invention provides a method of treatment of a human or non-human animal subject to combat inflammation arising from a condition associated with pain or a condition not associated with pain, said method comprising administering to said subject an effective amount of a physiologically tolerable strontium compound.... Agent: Sughrue Mion, Pllc

20070053995 - Therapy for the treatment of disease: Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.... Agent: Vista Ip Law Group LLP

20070053996 - Light-activated cation channel and uses thereof: The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention... Agent: Wilson Sonsini Goodrich & Rosati

20070053998 - Butanol extract of bidens pilosa: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; and p is 1, 2, 3, or 4. Also disclosed is use... Agent: Fish & Richardson Pc

20070053997 - Thermal herbal applicator: A herbal applicator that comprises of a flexible Main Housing which can be easily attached on to the body, is affixed with a flexible Heater Pad that connects to an electrical Power Source to, be regulated by an adjustable Temperature Controller, with the said flexible Heater Pad resting on a... Agent: Donn K. Harms Patent & Trademark Law Center

20070053999 - Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases: The present invention discloses a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases which comprises Radix Salviae Miltiorrhizae extract 5.0%-70.0%, Radix Notoginseng extract 10.0%-85.0%, Radix Astragali extract 5.0%-70.0%, and Bomeol or oil of Lignum Dalbergiae Odoriferae 1.0%-15.0%. The composition is active against cerebral ischemia and myocardial ischemia. The... Agent: Harness, Dickey & Pierce, P.L.C

20070054000 - Anti-obestic composition: The composition of the present invention comprises (1) a biologically effective amount of an extract of a plant of the genus Eucalyptus as an active ingredient, and (2) a biologically acceptable carrier or diluent, and is effective for inhibiting or preventing obesity (increase in weight), lipid storage disease, hyperlipemia, arteriosclerosis,... Agent: Sughrue Mion, Pllc

20070054001 - Methods and compositions to enhance endogenous igf production and their uses: An extract and procedure for extracting the polar constituents from plants of the Family Brassicaceae, specifically but not limited to the genus Lepidium. The extract has increased polar and decreased lipidic constituent concentrations with the ability to promote the expression and production of insulin-like growth factor. The extract makes the... Agent: Venable, Campillo, Logan & Meaney, P.c.

20070048215 - Chemical compound and assay: The present invention relates to a labelled ligand compound that is useful in a method of identifying, testing and/or screening of compounds modulating ion channels, in particular myocardial I?Kr# 191 channels such as those encoded by ERG, including hERG. The ligand compound is therefore of use to evaluate the affinity... Agent: Fish & Richardson P.C.

20070048216 - Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is... Agent: Coleman Sudol Sapone, P.C.

20070048220 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048221 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048219 - Antibody fragment-polymer conjugates and uses of same: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also... Agent: Heller Ehrman LLP

20070048218 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070048222 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048223 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048217 - F-18 peptides for pre targeted positron emission tomography imaging: F-18 radiolabeled peptides are prepared by reacting a peptide comprising a hydroxylamine, a thiosemicarbazide, a hydrazine or a free amine group with 4-[18F]Fluorobenzaledyde. Specific, non-limiting examples of F-18 radiolabeled peptides are described herein. The labeled peptides are useful, for example, in clinical positron emission tomography.... Agent: Faegre & Benson LLP Patent Docketing

20070048224 - Method and apparatus to sense hydration level of a person: A hydration sensor or sensing element configured to measure the hydration level of a user is disclosed. The sensing element can include a water-permeable material positioned in between two water-impermeable material. The sensing element can be coupled to a bottle of fluid, or a carrier with a timer. The sensing... Agent: Ipventure, Inc.

20070048225 - Nk3 receptor in vivo assay: The present invention relates to a method of assessing the in vivo potency of a NK3 receptor antagonist comprising: a) the non-human animal with the NK3 receptor antagonist of interest, b) treating an non-human animal with a NK3 R agonist treating, c) measuring the activity of the treated non-human animal,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070048227 - Multispecific noncovalent complexes for delivery of therapeutics: Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the... Agent: Faegre & Benson LLP Patent Docketing

20070048226 - Biochemical marker detection device: A probe device for detecting chemotherapy effectiveness, and methods of use are disclosed. The device includes a fiber optic probe element that can be injected into a tumor. The probe element is connected to an external controlling/measurement element, which injects a reagent through the probe and into the tumor. The... Agent: Mcdermott Will & Emery, LLP

20070048228 - Abuse-proofed dosage form: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention... Agent: Perman & Green

20070048229 - Buccal, polar and non-polar spray containing atropine: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide atropine for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, atropine, and optional taste mask and/or flavoring... Agent: Dickstein Shapiro LLP

20070048230 - Pheromone compositions and methods: Compositions and methods according to the inventive subject matter make use of human pheromones, and particularly androst-16-en steroids to achieve a desired non-behavioral effect in a person exposed to such compositions. Most preferably, contemplated compositions increase exercise strength and/or stamina, and reduce airway inflammation (e.g., sinusitis). Typically, the composition is... Agent: Robert D. Fish Rutan & Tucker LLP

20070048231 - Pheromone compositions and methods: Compositions and methods according to the inventive subject matter make use of human pheromones, and particularly androst-16-en steroids to achieve a desired non-behavioral effect in a person exposed to such compositions. Most preferably, contemplated compositions increase exercise strength and/or stamina, and reduce airway inflammation (e.g., sinusitis). Typically, the composition is... Agent: Robert D. Fish Rutan & Tucker LLP

20070048233 - Artificial tanning composition containing medication: A topical, artificial skin tanning composition comprises a mixture of a tanning substance which darkens a person's skin and a medication which is active on and/or absorbable by such person's skin. The tanning substance may be dihydroxyacetone, the medication may be turmeric, and the mixture is one which may be... Agent: John Mcculloch

20070048232 - Composition containing at least 50% by weight of dyestuffs: The invention relates to an eyeshadow composition containing at least 50% by weight, relative to the total weight of the composition, of at least one colouring agent that produces a colour by absorption of at least part of the visible spectrum.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070048234 - Compositions and methods for treating acne: This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a sunscreen,... Agent: King & Spalding

20070048235 - Moisturizing compositions: A composition comprising: an adduct of a vegetable oil and maleic anhydride; and a material chosen from a hydrolyzed keratin, hydroxyethyl urea, and/or a quaternized nitrogen moisturizing agent.... Agent: Colgate-palmolive Company

20070048236 - Peptide-based conditioners and colorants for hair, skin, and nails: Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants based are described. The peptide-based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070048238 - Color cosmetic compositions and methods: An anhydrous color cosmetic composition comprising a pigment component and a powder component, the improvement wherein the powder component includes microfine particle size powders in an amount sufficient to provide a composition that matches a plurality of skin shades in one, or more than one, skin tone category; and an... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070048237 - Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials: Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials includes a transparent substrate such as borosilicate, a layer of high refractive index material on the substrate, and alternating layers of low refractive index and high refractive index materials on the first layer, the total number of... Agent: Basf Catalysts LLC

20070048239 - Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials: Cosmetic and personal care formulations with goniochromatic non-quarter wave multi-quadrant multi-layer effect materials includes a transparent substrate such as borosilicate, a layer of high refractive index material on the substrate, and alternating layers of low refractive index and high refractive index materials on the first layer, the total number of... Agent: Basf Catalysts LLC

20070048240 - Applications of cross-linked silicone gel in personal care products: The present invention relates to the use of cross-linked silicone gel, in particular, a polymerization product of a polyorganohydrosiloxane, with the proposed INCI name (Dimethicone/polymethylalkyl siloxane copolymer), in cosmetic applications to provide unexpected characteristics related to formulations incorporating these silicone gels.... Agent: Coleman Sudol Sapone, P.C.

20070048241 - Emulsifying system: The present invention is an oil-in-water emulsion having a unique emulsifier system which is useful in high oil content products and products susceptible to phase inversion.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070048242 - Water washable hair removal (depilatory) compositions: Cosmetic hair removal (depilatory) compositions that provide complete hair removal in a single step and easy clean-up with water are disclosed. These viscous compositions are made of a mixture of a water soluble hair binding agent, a water soluble cross-linking agent for the hair binding agent, and a water soluble... Agent: Shyam K. Gupta Bioderm Research

20070048243 - Anti-aging composition containing criste marine and padina pavonica extracts: The present invention relates to topical compositions that include both Criste Marine and Padina Pavonica and their use for improving various properties of skin, including its appearance.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070048244 - Cosmetic composition for cleaning the skin: A cosmetic composition for cleansing skin has Ganoderma sp. spores in the amount of about 15% to about 50% (w/w) of the composition and collagen in the amount of about 50% to about 85% (w/w) of the composition.... Agent: Cooper & Dunham, LLP

20070048245 - Cosmetic composition to accelerate repair of functional wrinkles: The present invention relates to a composition consisting of a combination of peptides that regenerate the dermal matrix and a rapid acting muscle relaxant derived from the extract of the plant, Acemella oleracea. By limiting cutaneous deformation caused by the contraction of facial muscles the extract increases the efficiency of... Agent: Robert M. Skolnik

20070048246 - Novel skin care compositions: Skin care compositions are provided comprising a highly hydrophobic substance, an alkaryl polyfluorocarbon, particularly a substituted phenyl-polyfluoroacylamino propanamide, an alkanol and refined oils and the oil triglyceride fractions in sufficient amount to provide substantial homogeneity. When employed for hirsutism, optionally antioxidants and moisturizer are added. For use against wrinkles, additionally... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070048247 - Deodorizing tablets: A tablet that is capable of reducing odor when added to a liquid is provided. The deodorizing tablet may be used in a wide variety of applications in which odor control is desired, such as in toilets, water treatment/sewage systems, well water, bedpans, and so forth. In addition to providing... Agent: Dority & Manning, P.A.

20070048248 - Aptamer therapeutics useful in the treatment of complement-related disorders: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070048249 - Hydrophilized bactericidal polymers: A bactericidal polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal polymers, methods for rendering materials bactericidal, and methods for using... Agent: Brinks Hofer Gilson & Lione

20070048250 - Methods of treating concomitant constipation in a cancer treatment regimen including imexon: Methods of treating imexon-induced constipation in patients in conjunction with their participation in a cancer treatment regimen are disclosed herein. Embodiments of the invention include the treatment of imexon-induced constipation arising from the administration of imexon alone or in combination with other chemotherapeutic agents. Also disclosed are pharmaceutical compositions and... Agent: Townsend And Townsend And Crew, LLP

20070048251 - Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive: Methods for sealing an orifice in tissue in the body of a living animal using an adhesive formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. Methods for using the adhesive for medical and veterinary applications... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070048252 - Conjugates of the hydrophilic polymer and the molecules from boxwood extraction, and pharmaceutical compositions of the conjugates: The present invention relates to a group of conjugates of the hydrophilic polymers and the molecules from boxwood extraction. PEGylation process or the process alike was used to generate the conjugates, which have increased water solubility and prolonged the circulation half-life in the body.... Agent: GlobalIPServices

20070048256 - Chemokine beta-15: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine β-15 protein. Chemokine β-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070048259 - Cytokine zalpha11 ligand: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048260 - Cytokine zalpha11 ligand fusion proteins: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048254 - Generation of dendritic cells: A method is provided for expanding the population of mature dendritic cells in an individual subject. Proper timing of sequential delivery of Flt3-L and GM-CSF provides improved expansion of mature dendritic cell populations over methods currently employed in the art. The expansion of mature dendritic cells can be used to... Agent: Mirus Corporation

20070048255 - Method for treatment of demyelinating central nervous system disease: A method for treating demyelinating central nervous system diseases in a subject that comprises administering to the subject a composition comprising a therapeutically active amount of colony stimulating factor or CSF-like ligand. In a preferred embodiment of the present invention, the CSF is a GM-CSF. In a most preferred embodiment... Agent: Stites & Harbison PLLC

20070048253 - Natively glycosylated mammalian biological molecules produced by electromagnetically stimulating living mammalian cells: A composition is disclosed with the composition comprising a mixture of natively glycosylated mammalian biological molecules produced by electromagnetically stimulating living mammalian cells.... Agent: Ladas & Parry LLP

20070048257 - Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048258 - Use of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048274 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048275 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048276 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048277 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048263 - Il-21 production in prokaryotic hosts: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors,... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048262 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048265 - Methods of treating autoimmune diseases using il-21: Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048266 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048267 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048268 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048269 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048270 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048272 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048273 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048264 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048271 - Methos of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048261 - Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases: The present invention provides improved vaccines and immunogenic compositions comprising IL-12 or IL-23, and processes for the preparation of such vaccines and immunogenic compositions.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070048281 - Hcv combination therapy: The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon.... Agent: Nixon & Vanderhye, PC

20070048282 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070048284 - Cardiac arrhythmia treatment methods: Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia.... Agent: Banner & Witcoff

20070048286 - Method of treating dopaminergic and gaba-nergic disorders: It is shown here that hedgehog proteins possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons. Interestingly, hedgehog not only promotes dopaminergic neuron survival, but also promotes the survival of midbrain... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070048283 - Methods of inducing an immune response: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene... Agent: Agensys C/o Morrison & Foerster LLP

20070048287 - Molecular antigen array: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070048285 - Self-inactivating retroviral vector: The invention relates to retroviral vectors, especially to self-inactivating (SIN) gammaretroviral or lentiviral vectors, suitable for producing viral particles at high titers, which can be used for efficient gene transfer into mammalian cells, organs or organisms, e.g. for gene therapy. More specifically, the present invention provides modified 5′-promoter elements in... Agent: William Collard Collard & Roe, P.C.

20070048293 - Manipulation of pten in t cells as a strategy to modulate immune responses: The present invention relates to compositions and methods for modulating the expression and/or activity of PTEN in T cells, regulatory T cells, and CD4 T cells. The manipulation of PTEN provides a means for regulating an immune response.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070048294 - Method for inhibiting telomerase activity: The present application discloses a purified covalently closed antisense molecule, which specifically inhibits expression of human telomerase by specifically binding to nucleic acid encoding human telomerase.... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20070048295 - Method for preparing alginate capsules: The present invention relates to a method for preparing alginate capsules, including incorporating at least one prebiotic and at least one pancreatic digested protein in the wall of an alginate capsule. The present invention also relates to the alginate capsules prepared by the method.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070048292 - Cell-containing sheet: In accordance with the present invention, an implant in which cells are arranged in a fine pattern that is available for immediate implantation and that does not need to be removed after implantation is provided. The present invention relates to a cell-containing sheet, which comprises cells and a support comprising... Agent: Sughrue Mion, PLLC

20070048289 - Cellular intervention to treat damaged myocardium: A system and method for treating damage myocardial tissue includes delivering replacement cells to the myocardium of a patient and electrically stimulating the spinal column of the patient to affect a cellular environment within the myocardium.... Agent: Medtronic, Inc.

20070048290 - Development of natural killer cells and functional natural killer cell lines: The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines. Additionally,... Agent: Trask Britt

20070048291 - Method and material for enhanced tissue-biomaterial integration: The present invention relates to the covalent binding of a hydrogel to an extracellular matrix (ECM). The integration of the hydrogel with the tissue is superior to that in previous techniques. Moreover, unlike previous techniques, the present invention does not require a photoinitiator. Potential therapeutic applications include tissue repair and... Agent: Bell, Boyd, & Lloyd LLC

20070048288 - Shear thinning polymer cell delivery compositions: Cell delivery compositions including shear thinning polymers and their use in cell delivery are described. The cell delivery compositions include shear thinning polymers that confer higher viscosity when at rest and decreased viscosity when subject to shear stress when dissolved or suspended in a carrier liquid. These shear thinning properties... Agent: Mueting, Raasch & Gebhardt, P.A.

20070048296 - Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation: The invention provides methods and compositions that include a nutraceutical supplement, antibiotic, and metal chelating agent that is administered to a patient to treat or prevent pathological calcification and or plaque formation as associated with Nanobacteria Calcifying Nano-Particles and/or diseases caused there-from, The method includes the administration of a therapeutically... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070048297 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors,... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070048298 - Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same: The present invention is directed to a method for treating autoimmune diseases comprising administering RBAp48 production suppressor or inhibitor; a screening method for a preventive or therapeutic agent for autoimmune diseases comprising determining RBAp48 production suppressing effect or inhibitory effect of a sample; a diagnosis agent or a diagnosing kit... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070048300 - Antibodies having altered effector function and methods for making the same: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.... Agent: Lahive & Cockfield, LLP

20070048299 - Methods of inducing an immune response: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene... Agent: Agensys C/o Morrison & Foerster LLP

20070048301 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070048304 - Method of treating allergy using antibody against human interleukin-5 receptor alpha chain: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor α chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor α chain immunologically by means of these... Agent: Fitzpatrick Cella Harper & Scinto

20070048303 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048302 - Peptides of il-2: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070048305 - Cd147 binding molecules as therapeutics: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070048310 - Human ataxin-1-like polypeptide imx97018: This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.... Agent: Immunex Corporation Law Department

20070048306 - Method for generating anti-variable region monoclonal antibodies: Methods for generating anti-variable region monoclonal antibodies in rodents are disclosed. The anti-variable region mAbs are useful as therapeutic agents, diagnostic agents or research reagents.... Agent: Philip S. Johnson Johnson & Johnson

20070048307 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zyctor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048308 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048309 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048312 - Anti-addl antibodies and uses thereof: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.... Agent: Licata & Tyrrell P.C.

20070048311 - Anti-interferon-alpha antibodies: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders... Agent: Merchant & Gould PC

20070048319 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048315 - Engineered anti-il-23 antibodies: Engineered antibodies to human IL-23pl9 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.... Agent: Dnax Research Inc. Legal Department

20070048313 - Hybridoma cell lines and monoclonal antibodies recognizing prox1: Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cells.... Agent: Connolly Bove Lodge & Hutz LLP

20070048318 - Method for treating psoriasis: A method for treating psoriasis. An antagonist to IL-17Dβ9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5).... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048316 - Method of reducing proliferation of cells in a mammal: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides,... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048317 - Method of treating fibroproliferative disorders: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides,... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048314 - Process for preparing purified drug conjugates: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.... Agent: Leydig Voit & Mayer, Ltd

20070048322 - Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis: Nucleic acids encoding tRNA synthetase polypeptides useful for regulating angiogenesis are disclosed. Methods of making and using such nucleic acids are also disclosed.... Agent: Olson & Hierl, Ltd.

20070048320 - Method for indentifying modulators of ppil2 useful for treating alzheimer's disease: Methods for identifying modulators of PPIL2 are described. The methods are particularly useful for identifying analytes that antagonize PPIL2's effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease.... Agent: Merck And Co., Inc

20070048321 - Method for the treatment of fibrosis: Disclosed is a method of treating fibrosis in a human or animal subject. The method comprises administering to the subject an effective amount of an antibody to an integrin or fragment thereof.... Agent: Fish & Richardson

20070048323 - Antibody treatment of lipomatous tumors: A method of treating lipomatous tumors in mammals such as humans or companion animals is described. The treatment of lipomatous tumors use antibodies derived from adipose tissue of a mammal donor. The methods of the present invention are effective against both benign and malignant lipomatous tumors. The antibodies of the... Agent: Raymond A. Miller Pepper Hamilton LLP

20070048324 - Antitumor antibodies, proteins, and uses thereof: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.... Agent: Lahive & Cockfield, LLP

20070048325 - Combination therapies for inhibiting integrin-extracellular matrix interactions: The present application relates to compositions of ECM antagonists and their use in methods for treating angiogenic-dependent conditions. The ECM antagonists can bind the same or different ECM component. The present application also relates to compositions of ECM antagonists and cancer therapies and their use in methods for preventing, treating... Agent: Wilson Sonsini Goodrich & Rosati

20070048326 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070048327 - Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy: Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity.... Agent: Jones Day

20070048328 - Allergy prevention method or treatment method, diet and oral drug: The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg... Agent: Birch Stewart Kolasch & Birch

20070048329 - Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor: Immunogenic cytotoxic T cell epitope peptides of Epstein Barr Virus LMP1 protein are provided having between nine and seventeen amino acids and minimal consensus sequences selected from QRH, AGNDG, QNW, VLYS and DSNSNE. These peptides, either individually or in polyepitope constructs, are useful in pharmaceutical compositions, vaccines and methods of... Agent: Buchanan, Ingersoll & Rooney PC

20070048330 - Optimized multi-epitope constructs and uses thereof: The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070048331 - Non-toxic mutants of pathogenic gram-negative bacteria: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains... Agent: Viksnins Harris & Padys Pllp

20070048333 - Cd4+ t-lymphocyte-specific hepatitis c virus-epitopes: The invention relates to Hepatitis C virus epitopes which are specific in relation to CD4+ T lymphocytes, in addition to vaccinations which contain said epitopes.... Agent: Foley And Lardner LLP Suite 500

20070048332 - Stabilized liquid anti-rsv antibody formulations: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,... Agent: Jones Day

20070048335 - Methods for treating pain and hyperhidrosis: Agents for treating pain and for treating hyperhidrosis are disclosed. The agent comprises a light chain of a botulinum toxin or a fragment thereof and an alpha-2 adregenergic receptor pan agonist.... Agent: Allergan, Inc.

20070048334 - Use of a botulinum toxin to improve gastric emptying and/or to treat gerd: Methods for treating gastric disorders, such as GERD and delayed gastric emptying, by intramuscular administration of a botulinum toxin to a head, neck and/or shoulder muscle of a patient with a gastric disorder.... Agent: Stephen Donovan Allergan, Inc.

20070048336 - Combination therapy of peptide vaccination and estramustine treatment: A method for treating a prostate cancer, which comprises administering a therapeutically effective amount of a cancer antigen peptide-associated agent and a lower dose of an estramustine or a salt thereof to a patient in need thereof, and a pharmaceutical composition thereof are provided.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070048337 - Aldol-crosslinked polymeric hydrogel adhesives: Adhesives formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. The use of the adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070048338 - Compositions and methods for surface treatment in medical and surgical procedures: The present invention comprises compositions and methods for contemporaneously anesthetizing and antiseptically treating or pretreating anatomic surfaces for invasive surgical or treatment procedures. In particular, compositions and methods according to the present invention are used to treat ocular surfaces for intravitreal injections and other ophthalmic procedures. Compositions of the present... Agent: Troutman Sanders LLP

20070048340 - Multi step patterning of a skin surface: Methods and systems for treating skin for aesthetic or health or other purposes are described. According to various embodiments, photoresponsive materials and light are delivered in controlled fashions to produce a patterned distribution of one or more material in or upon the skin.... Agent: Searete LLC Clarence T. Tegreene

20070048339 - Structured materials: The present invention relates to a method for preparing a structured material comprising: providing a hydrophilic particle such as hydrophilic silicas, silicates, dextrins, starches, minerals, sodium bicarbonate, clays, sugars, polyols, dried flavors/fragrances, hydrocolloids, proteins, celluloses, methylcellulose, hydroxypropyl methyl cellulose, flours of wheat, corn, potato, and rice, dried milk and dairy... Agent: International Flavors & Fragrances Inc.

20070048342 - Anti-microbial and anti-fungal additives to provide mold and mildew resistance: A naturally derived additive to fibrous materials and to building materials for imparting resistance to mold and mildew growth, including one or more additives extracted from a group of plant species, such as those from the families of Myrtacea, Rutaceaea, Zingiberaceae and Labiatae and essential oils derived from specific species... Agent: Vangelis Economou C/o Iphorgan Ltd

20070048344 - Antimicrobial composition: An antimicrobial composition that involves a synergistic mixture in terms of active agents, of a primary antimicrobial agent, such as polyhexamethylene biguanide (PHMB), a secondary antimicrobial agent, and optionally an organic acid against various kinds of microbes is described. Various additional processing aids, such as alcohols and surfactants, may also... Agent: Kimberly-clark Worldwide, Inc.

20070048345 - Antimicrobial composition: An antimicrobial composition that contains an antimicrobial agent and a sugar alcohol is provided. The sugar alcohol is more generally more biocompatible and biodegradable than the antimicrobial agent. In addition, without intending to be limited by theory, it is believed that sugar alcohols increase the attraction of the antimicrobial agent... Agent: Dority & Manning, P.A.

20070048343 - Biocidal premixtures: This invention provides a novel biocidal premixture, particularly useful as a component in cellulose reinforced thermoplastic composites. The inventive biocidal premixture includes a combination of a biocidal agent, either a coupling agent, a lubricant, or both. The addition of such biocidal premixtures to cellulose reinforced thermoplastic composite materials offers improved... Agent: Colleen D. Szuch Honeywell International Inc. - Patent Department

20070048346 - Insect proof boards: The object of the present invention is to impart lasting excellent insect proof property to boards. According to the present invention, an insecticidal treatment liquid which contains an insecticide in an aqueous dispersion of colloidal silica is applied to the surface of a coat on a substrate applied with coating.... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070048341 - Ticktape: The Problem with hiking in the woods is the infestation of ticks, when attached to the hiker, crawls on the person and attaches itself to the skin. As the tick burrows its head under the skin, it transmits certain diseases, leading to high fever, breathing problems, paralysis, even death in... Agent: Salvatore Ribera

20070048350 - Antithrombotic coating for drug eluting medical devices: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20070048351 - Drugs coated on a device to treat vulnerable plaque: A treatment for vulnerable plaque may include a device having a polymeric coating that contains a statin and/or one or more other drugs, where the statin and/or one or more other drugs may be locally released in a sustained fashion at the point of insertion of the device. The coating... Agent: Patton Boggs LLP

20070048347 - Intra-oral device for treating obesity: The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070048348 - Lubricious composites for medical devices: A medical device having at least one composite region thereon formed of composite material comprising a polymer and a fluorinated sol-gel derived ceramic. The composite material is useful as a coating material for imparting a low coefficient of friction to a substrate.... Agent: Vidas, Arrett & Steinkraus, P.A.

20070048352 - Method for attachment of biomolecules to medical device surfaces: A method for making a medical device having at least one biomolecule immobilized on a substrate surface is provided. One method of the present invention includes immobilizing a biomolecule comprising an unsubstituted amide moiety on a biomaterial surface. Another method of the present invention includes immobilizing a biomolecule on a... Agent: Medtronic, Inc.

20070048349 - Surface-modified medical devices and methods of making: A surface-modified medical device comprises a hydrophilic coating that comprises units of a hydrophilic monomer and a coupling agent that has coupling functional groups, at least a portion of which is coupled to the surface functional groups of the medical device. A method for producing such a surface-modified medical device... Agent: Bausch & Lomb Incorporated

20070048353 - Production method of food and beverage products with high content of gamma-aminobutyric acid and food and beverage products with high content of gamma-aminobutyric acid: A method for producing food and beverage products with a high content of γ-aminobutyric acid, wherein processed tomato products whose filtrate has a coloring degree between 0.02 and 0.2 when sugar content is adjusted to 3% are fermented with lactic acid bacteria, and food and beverage products with a high... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20070048354 - Synthetic nutritional formulations: The present invention provides a synthetic nutritional formulation comprising a substantially pure free N-acetyl glucosamine in concentrations effective for enhancing organ development, enhancing an immune response, or increasing tissue repair or healing in a subject. A synthetic nutritional formulation of the invention may optionally comprise one or both of substantially... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070048358 - Antimicrobial substrates: A synergistic antimicrobial composition containing at least two kinds of antimicrobial agents, including poly-hexamethylene biguanide (PHMB), stably associated to a material substrate is described. The substrate can take the forms of an anti-infection face mask, medical devices, or surgical instruments.... Agent: Kimberly-clark Worldwide, Inc.

20070048356 - Antimicrobial treatment of nonwoven materials for infection control: A material substrate having at least part of a surface treated with an antimicrobial composition is described. The antimicrobial composition exhibits at least a 3 log10 CFU reduction within a period of about 30 minutes after contact with various species of a broad spectrum of microorganisms. The substrate can be... Agent: Kimberly-clark Worldwide, Inc.

20070048359 - Exfoliating scrubber: A scrubber mitt comprising a backing, a plurality of loops and a cavity. The backing may have an inner side and an outer side. The plurality of loops may be attached to the outer side. The cavity may be defined by the inner side. The cavity is adapted to fit... Agent: SocalIPLaw Group LLP

20070048357 - Fibrous wiping products: Sheet-like products are disclosed having a controlled equilibrium moisture content. The sheet-like product may comprise a dry product or a pre-moistened product. The sheet-like product, for instance, may comprise a facial tissue, a bath tissue, a paper towel, a napkin, or a wet wipe, such as pre-moistened bath tissue. In... Agent: Dority & Manning, P.A.

20070048355 - Non-irritating solvent-borne polymeric coatings for application to the skin: A method and composition for reducing or eliminating stinging that may accompany application of topical solution of a skin-compatible polymeric material to a skin wound, abrasion, burn or other skin injury. The topical solution may contain one or more skin-irritating chemicals, such as diethyl ether, ethanol, ethyl acetate, methyl acetate,... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070048360 - Pharmaceutical compositions with melting point depressant agents and method of making same: The invention relates to the use of chemical fragrance ingredient to lower the melting point of active agents, thereby changing crystalline active agents into an amorphous state. The invention also relates to methods of enhancing the transdermal or transmucosal skin permeation or skin penetration of pharmacologically active agents to patients... Agent: Winston & Strawn LLP Patent Department

20070048361 - Patches and uses thereof: A patch comprising a support having electrostatic properties is provided wherein a periphery of the support is coated with an adhesive material, and all or part of the non-adhesive surface of the support is covered with at least one biologically active substance in the form of particles that is adhered... Agent: Heslin Rothenberg Farley & Mesiti PC

20070048362 - General purpose electrolyte solution composition for iontophoresis: A single electrolyte solution composition may be used in an anode side and in a cathode side of an iontophoresis device. The electrolyte solution may include a compound having an oxidation-reduction potential lower than that of water, the compound including, in combination, both a component that is likely to be... Agent: Seed Intellectual Property Law Group PLLC

20070048365 - Edible coded microsubstrate for pharmaceuticals: A system for verifying product authenticity. A verification system may include: coded microstructures contained within a product. In particular implementations, such as pharmaceuticals, the microstructures are edible and, in some cases, even digestible. Glyph coding may be included to enhance the readability of the microstructures that may have been damaged... Agent: Booth Udall, PLC

20070048364 - Free flowing granules containing carbomer: Methods for making granules containing a carbomer whereby the carbomer is mixed with a hot-melt binder that does not lower the glass transition temperature of the carbomer more than 20° C., the binder is subjected to a temperature at which the hot-melt binder melts or becomes tacky, thus binding the... Agent: Howard Eisenberg, Esq.

20070048363 - Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof: The invention relates to a pharmaceutical agent, particularly a chemotherapeutical agent, comprising cis-diammoniumdichloro-trans-dihydroxoplatinum(IV) or salts and/or derivatives thereof in the form of capsules, tablets, creams, ointments and infusion solutions, and to the production of said pharmaceutical agent; the invention also relates to the use of such pharmaceutical agents in the... Agent: Joyce Von Natzmer Hall, Vande Sande & Pequigot, LLP

20070048366 - Gelatin-based coatings having improved durability: The present invention relates to a process for manufacturing gelatin products that have improved stability, particularly as to the dissolution rates and/or reduced degree of crosslinking and the gelatin formulations per se. A further aspect of the invention is use of the improved gelatin compositions for use as a coating... Agent: Philip S. Johnson Johnson & Johnson

20070048367 - Herbal composition for treating morning sickness: An herbal composition for treating morning sickness includes a mixture of vitamin B6, folic acid, ginger root extract, and red raspberry leaf.... Agent: Julia Church Dierker Dierker & Associates, P.C.

20070048368 - Dosage form comprising liquid formulation: A sustained release dosage form includes a capsule made of a thermoplastic polymer having a softening point below 200° C. and an orifice formed or formable within the capsule, an emulsion formulation contained within the capsule, and an expandable composition within the capsule remote from the orifice. The emulsion formulation... Agent: Dewipat Incorporated

20070048374 - Bazedoxifene acetate formulations: The present invention is directed to formulations of bazedoxifene acetate that have reduced polymorph conversion, compositions containing the same, preparations thereof, and uses thereof.... Agent: Cozen O' Connor, P. C.

20070048373 - Dried milled granulate and methods: The present invention relates to a method of producing a dried wet granulate having a desirable average particle size and particle size distribution and dosage forms made from that granulate.... Agent: Cima Lerner, David Et Al

20070048372 - Method for treating non-inflammatory osteoarthritic pain: A method for treating non-inflammatory osteoarthritic pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof.... Agent: Harness, Dickey, & Pierce, P.l.c

20070048369 - Mucosal delivery tablet: Mucoadhesive tablets have a convex surface, a diameter to cup depth ratio of 4-20 and a cup depth to edge thickness ratio of greater than 0.75 swiftly adheres and conforms to the contacting tissue. The tablets are used to administer actives such as, for example, benzocaine.... Agent: National Starch And Chemical Company

20070048370 - Pharmaceutical formulation for salts of monobasic acids with clopidogrel: A pharmaceutical formulation in the form of a tablet which contains, as active substance, a salt of a monobasic acid with clopidogrel is disclosed herein.... Agent: Smith Patent Consulting Consulting, LLC

20070048371 - Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily: Therapeutic formulations of guanfacine in a once a day single dose form which have useful overall tablet sizes are disclosed.... Agent: Millen, White, Zelano & Branigan, P.C.

20070048375 - Effervescent preparation of a basic medicinally active substance: The present invention relates to an effervescent preparation comprising an effervescent composition, at least one basic medicinally active substance and, where appropriate, one or more further active ingredients, characterized in that alkalization of the urine and thus increased accumulation of the basic medicinally active substance is avoided, to medicaments comprising... Agent: Richard S. Bullitt Bayer Healthcare LLC

20070048377 - Drug compositions containing controlled release hypromellose matrices: This invention is directed to a controlled release formulation for an oral dosage form that is formulated into a swellable, hydrophilic matrix. The controlled release formulation contains a mixture of hypromellose and polyvinyl acetate phthalate and allows pharmaceutically active ingredients combined therewith to be released in a controlled release manner.... Agent: Lucas & Mercanti, LLP

20070048376 - Sustained release formulations of nalbuphine: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070048378 - Nanoparticulate anticonvulsant and immunosuppressive compositions: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070048380 - Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof: The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in... Agent: White & Case LLP Patent Department

20070048379 - Valproate tablet: A process for preparing a pharmaceutical tablet comprising: (a) mixing a valproate compound with at least one excipient to form a premix; (b) adding a sufficient amount of water to the premix of Step (a) and mixing to form a wet granulation; (c) drying the wet granulation of Step (b)... Agent: Novartis Corporate Intellectual Property

20070048381 - Methods for promoting growth of bone, ligament, and cartilage: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of a zvegf3 protein in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of... Agent: Zymogenetics, Inc. Intellectual Property Department

20070048382 - Bone cement composition and method of making the same: Disclosed herein is a composition suitable for use in spinal surgery. The composition generally includes a reaction product or settable mixture of first and second components, the first component including a spray-dried inorganic filler, a radical donor, and a pre-polymerized vinyl polymer, and the second component including a radical scavenger,... Agent: Marshall, Gerstein & Borun LLP

20070048384 - Pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.... Agent: Robert Deberardine Abbott Laboratories

20070048383 - Self-assembled endovascular structures: The present invention is directed to the formation of structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling... Agent: Mayer & Williams PC

20070048385 - Microcapsules by coacervation containing a pharmaceutical incorporated in the coating polymer: Microcapsules containing an active ingredient, constituted by a core coated with a polymer membrane, characterized in that the active ingredient is incorporated in the polymer coating layer, and in that said layer is applied using microencapsulation techniques (coacervation by means of phase separation). The microcapsules; thus produced have excellent properties... Agent: Mark P Levy Thompson Hine

20070048386 - Medicament for treating inflammatory and non-inflammatory arthritis: A medicament for the treatment of inflammatory and non-inflammatory arthritis that includes the following ingredients: arnica, calendula, glucosamine, salicylic acid, hamamelis, emu oil and wild yam. The medicament may be in the form of an ointment, cream, gel, emulsion or liquid solution that is topically applied directly to the affected... Agent: Maine & Asmus

20070048387 - Tissue disruption treatment and composition for use thereof: The present invention relates to an agent having activity in the treatment of a tissue disruption. In particular the present invention relates to a composition comprising an effective amount of an active fraction having tissue healing properties... Agent: Edwards & Angell, LLP

20070048388 - Stabilized and preserved ketotifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.... Agent: Novartis Corporate Intellectual Property

20070048389 - Stabilized and preserved ketotifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.... Agent: Novartis Corporate Intellectual Property

20070048390 - Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a... Agent: Darby & Darby P.C.

20070048391 - Composition for reduction of scar formation on wound scar: The present invention relates to a pharmaceutical composition for inhibiting scar formation on wound region which consists of hyaluronic acid and alkalization agent such as sodium bicarbonate, NaOH, and KOH.... Agent: King & Spalding LLP

20070048392 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families. Cissus, Vernonia and Brillantasia. Such compositions have beneficial activity principlally in controlling weight gain and obesity, especially in conjunction with chitosan or a chilosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP

20070048393 - Topical turmeric skin care products: A topical skin care product containing therapeutic concentrations of turmeric and other constituents which enable the product to be used for cosmetic, protective, and healing purposes without the yellow staining of skin or clothing.... Agent: Mcculloch PLC

20070048396 - Anti-inflammatory compositions and methods of use: Provided are anti-inflammatory compositions comprising (a) an anti-inflammatory agent selected from the group consisting of olive leaf extract, holly herb, sappan wood, feverfew, and combinations of two or more thereof, and (b) an anti-inflammatory agent comprising at least one lipophilic aminoacid and at least one metal salt. Also provided are... Agent: Philip S. Johnson Johnson & Johnson

20070048397 - Anti-inflammatory compositions and methods of use: Provided are anti-inflammatory compositions comprising (a) an anti-inflammatory agent selected from the group consisting of olive leaf extract, holly herb, sappan wood, feverfew, and combinations of two or more thereof, and (b) an anti-inflammatory agent comprising at least one lipophilic aminoacid and at least one metal salt. Also provided are... Agent: Philip S. Johnson Johnson & Johnson

20070048395 - Antibacterial treatment and composition: A method for treating a bacterial infection in a subject by administration of an effective amount of centaurein alone or in combination with a bacteriocide. Also described is a composition containing an effective combined amount of centaurein and a bacteriocide useful for treating a bacterial infection in a subject.... Agent: Fish & Richardson PC

20070048394 - Immunomodulatory compositions: Methods useful, for example, in identifying plant compositions that have immunomodulatory activity. Also disclosed is an Asteraceae plant immunomodulatory composition useful for increasing an immune response, e.g., IFN γ or IL-2 transcription.... Agent: Fish & Richardson PC